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ABSTRACT 
The Mixed Lineage Leukemia (MLL) gene can participate in chromosomal 
translocations which generate a fusion protein leading to aggressive, acute leukemia.  
These translocations may occur spontaneously or following previous treatments with 
particular chemotherapy agents.  Compared to other types of acute leukemia, MLL-
associated leukemias have a poor prognosis.  A better understanding of how MLL fusion 
proteins contribute to leukemia is necessary in order to develop more effective 
treatments. 
MLL fusion proteins retain the amino-terminal portion of MLL including the 
CXXC DNA-binding domain while the carboxy-terminal portion of the oncoprotein is 
comprised of the fusion partner.  The MLL CXXC domain is a zinc-coordinating 
structure which binds to non-methylated DNA within the promoter region of target genes.  
The CXXC domain is located within a functional repression domain which is known to 
interact with cofactor proteins that modulate target gene expression.  In my dissertation 
project, I investigated the functional role of amino acids within the CXXC domain to 
determine how specific residues contribute to the leukemogenic capacity of MLL fusion 
proteins. 
The closest homolog of MLL, MLL2 (alternatively named MLL4), also contains a 
similar CXXC domain, yet an artificial MLL2 fusion protein is unable to transform cells 
in vitro.  Knowing that the CXXC domain is a critical component of MLL fusion 
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proteins, I hypothesized that specific amino acid differences between MLL and MLL2 
CXXC domains account for differences in leukemogenic capacity.  To test this 
hypothesis, the MLL2 CXXC domain was cloned into the context of the well-studied 
MLL-AF9 fusion protein to generate an artificial MLL/MLL2-AF9 chimera.  Amino acid 
substitutions within the MLL2 CXXC domain were then introduced to restore residues to 
the MLL amino acid sequence within this synthetic chimera.  Retroviral transduction of 
bone marrow progenitor cells with the wild type or mutant chimeric MLL/MLL2-AF9 
fusions was performed to measure proliferation capacity in a methylcellulose colony 
assay.  Colony forming ability and cell proliferation were then measured along with 
observations in cellular morphology and target gene expression to determine the 
functional contributions of specific residues within the CXXC domain of the fusion 
proteins.  In vitro binding studies were performed between MLL or synthetic 
MLL/MLL2 repression domain protein fragments and cofactor proteins to determine if 
there were differences in protein interactions which could account for the observed 
functional differences.  By comparing the residues of the MLL and MLL2 CXXC 
domains, critical amino acids were identified on both the DNA-binding surface and on 
the opposite, non-DNA-contact surface of the CXXC domain that contribute to 
leukemogenic transformation. 
Cysteine 1188 of the MLL CXXC domain is the only non-zinc-coordinating 
cysteine residue within the CXXC domain.  This residue is critically positioned on the 
DNA-binding surface, and our laboratory has previously shown that mutation of this 
residue can disrupt the ability of the CXXC domain to bind to DNA.  With a critical 
location on the DNA-binding surface and potential susceptibility to post-translational 
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modification, I hypothesized that the side chain of Cys1188 may be physiologically 
altered to regulate DNA-binding affinity.  Transformed MLL-AF9 progenitor cells were 
treated with modifying agents or grown under conditions of varying oxygen 
concentration, and cell viability and colony forming ability were measured.  The MLL-
AF9 cells showed a modest increase in susceptibility to parthenolide treatment in an in 
vitro colony assay compared to control cells suggesting that Cys1188 may be altered 
through redox regulation.  Growth under conditions of varying oxygen levels, however, 
showed no significant differences in proliferation of wild type or control cells.  These 
results build on the initial studies of Cys1188 and the MLL CXXC domain conducted in 
our lab and provide valuable direction for future investigations which may eventually 
allow for therapeutic targeting of the CXXC domain in these aggressive forms of MLL-
associated leukemia. 
1 
CHAPTER 1 
 
INTRODUCTION 
 
The Mixed Lineage Leukemia (MLL) gene is involved in translocations with more 
than 60 possible fusion partners leading to aggressive, acute leukemias with poor 
prognosis.  The resulting chimeric fusion protein retains the N-terminal portion of MLL 
including the CXXC DNA-binding domain, while the C-terminal portion of the 
oncoprotein is comprised of the fusion partner1, 2.  The CXXC domain is found within a 
functionally-defined repression domain and binds to non-methylated CpG DNA3-5.  This 
CXXC DNA-binding domain contains a clustering of eight cysteines which coordinate 
two zinc ions and is essential for the transformation capacity of cells expressing an MLL 
fusion protein4.  The closest homolog of MLL, MLL2 (alternatively named MLL4), also 
contains a similar CXXC domain which preferentially binds non-methylated CpG DNA 
but with lower affinity than the MLL CXXC domain (Bushweller laboratory, University 
of Virginia, unpublished)6, 7.  Interestingly, cells expressing an artificial MLL2 fusion 
protein do not transform primary bone marrow cells and require the substitution of the 
MLL CXXC domain plus the ‘post-CXXC’ residues—a region comprising the majority 
of the MLL repression domain—in order to become immortalized in vitro7.  I 
hypothesized that amino acid differences between the CXXC domain or the repression 
domain of MLL and MLL2 must contribute to these functional differences.  Specific 
amino acids along the DNA contact interface may play a role in differential DNA-
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binding affinity.  In addition, our lab has previously shown that the repression domain of 
MLL (containing the CXXC domain) binds to class I histone deacetylases (HDACs 1 and 
2), polycomb group proteins (HPC2 and BMI-1), and the co-repressor C-terminal-binding 
protein (CtBP)8.   Recently, a co-activator protein, PAF1, was also shown to bind to this 
same region of MLL9, 10.  Differential binding of these cofactor proteins to MLL and 
MLL2 may affect overall function but might also contribute to CXXC DNA-binding 
affinity. Cysteine 1188, the only non-zinc-coordinating cysteine residue within the 
CXXC domain, is critically positioned on the DNA-binding surface and adjacent to one 
of the conserved cysteines involved in zinc coordination11.  Previous studies conducted in 
our lab showed that mutation of Cys1188 to aspartate completely abrogated the ability of 
the CXXC domain to bind DNA and prevented both in vitro immortalization and 
development of leukemia in mice when introduced in the context of a MLL fusion 
protein11.  In contrast, mutation of Cys1188 to alanine retained MLL’s ability to bind 
CpG DNA, as well as to immortalize in vitro and in vivo in the context of the fusion 
protein11.  With a critical location on the DNA-binding surface of the CXXC domain and 
susceptibility to redox regulation, I hypothesized that the side chain of Cys1188 may be 
physiologically altered to regulate DNA-binding affinity, allowing this residue to 
function as a molecular switch that regulates the binding of MLL to its non-methylated 
CpG DNA targets. 
Hypothesis: Specific amino acid residues of the MLL and MLL2 CXXC domains 
function to alter DNA binding, cofactor binding, and susceptibility to post-translational 
modification—critical features of MLL that determine leukemogenic capacity. 
3 
Aim 1: Determine how differences in the MLL CXXC domain and the MLL2 CXXC 
domain contribute to the different transformation capacities of MLL/MLL2-
AF9 fusion proteins. 
MLL and MLL2 are paralogs with high sequence homology.  Both proteins 
contain similar functional domains including the CXXC DNA-binding domain with eight 
conserved Zn-coordinating cysteine residues.  With such similarity, it is intriguing that 
MLL2 is unable to compensate for the embryonic lethality observed in Mll -/- mice12.  
Moreover, MLL2 has not been associated with translocations causing leukemia like MLL.  
The CXXC domain and the ‘post-CXXC’ residues of the larger repression domain 
(residues 1149-1337 of MLL) have been shown to account for the differences in 
leukemogenic capabilities of these proteins7.  However, the specific amino acid residues 
within the repression domain which account for this difference have not yet been 
identified.  The repression domain of MLL has previously been shown to bind to cofactor 
proteins but it is not currently known if these same co-repressors bind to MLL28-10.  I 
hypothesized that specific amino acid differences between MLL and MLL2 contribute to 
variable DNA-binding affinities of the CXXC domains and to variable recruitment of 
cofactor proteins which regulate transcription of MLL/MLL2 target genes.  The first aim 
of my dissertation proposed to explore how these specific amino acid differences affect 
the critical functioning of the CXXC domain and alter the leukemogenic capacity of these 
translocations. 
 
 
4 
Aim 2: Determine the role of Cysteine 1188 in the regulation of the MLL CXXC 
domain binding to non-methylated CpG DNA. 
Cysteine 1188 of the MLL CXXC domain is the only non-zinc-coordinating 
cysteine residue within the CXXC domain and is highly conserved across vertebrate 
orthologs of MLL.  Our lab showed that this residue is critically positioned on the DNA-
binding surface and adjacent to one of the conserved cysteines involved in zinc 
coordination11.  Mutation of Cys1188 to aspartate completely abrogated the ability of the 
CXXC domain to bind DNA even though it is not involved in direct interactions with 
DNA11.  Zinc finger motifs containing a zinc ion tetrahedrally coordinated to cysteine or 
histidine groups are relatively common within DNA-binding proteins and can be subject 
to redox regulation at free cysteine residues to alter protein function13.  The hypoxic 
niche (in which hematopoiesis takes place and leukemia stem cells can reside) may 
protect Cys1188 of the MLL CXXC domain from oxidation.  With a critical location on 
the DNA-binding surface of this domain and susceptibility to post-translational 
modification, I hypothesized that the side chain of Cys1188 may be physiologically 
altered to regulate DNA-binding affinity, allowing this residue to function as a molecular 
switch that regulates the binding of MLL to its non-methylated CpG DNA targets. 
It is not well understood how the balance of gene activation and repression is 
functionally regulated during normal hematopoiesis or MLL-associated leukemia.  The 
CXXC DNA-binding domain and the ‘post-CXXC’ residues of the MLL repression 
domain have been shown to be essential for the transformation capacity of MLL fusion 
proteins2, 7, 11.  By studying specific amino acid residues of the MLL CXXC domain, the 
goal of my dissertation was to better understand functional features that contribute to 
5 
MLL’s ability to bind to DNA and to cofactor proteins and the potential post-translational 
modifications which we hypothesized are critical determination features for MLL-
associated leukemia.  My work serves as a starting point for therapeutic targeting of the 
MLL CXXC domain to alter leukemogenic capacity and, ultimately, lead to better 
clinical outcomes for these devastating forms of acute leukemia. 
6 
CHAPTER 2 
 
LITERATURE REVIEW 
The Mixed Lineage Leukemia (MLL) gene and leukemia 
 The Mixed Lineage Leukemia (MLL) gene was first identified for its involvement 
in translocations at the 11q23 locus associated with acute leukemia14.  The MLL gene 
(also called MLL1, HRX, HTRX, or ALL-1) derives its name from the clinical presentation 
associated with its cytogenetic aberration: patients with these chromosomal 
rearrangements develop the pathological phenotype of acute lymphoid leukemia (ALL), 
acute myeloid leukemia (AML), or a mixed lineage leukemia15-18.  MLL genetic 
abnormalities account for 5-10% of ALL or AML cases19, 20.  The incidence of MLL-
associated leukemia is significantly higher, though, in two distinct populations of 
leukemia cases: de novo infant leukemias and secondary leukemias which develop 
following chemotherapy with high doses of DNA topoisomerase II inhibitors21, 22.  
Furthermore, MLL leukemias are particularly aggressive compared to other types of 
leukemia and are associated with relatively dismal outcomes with five-year survival rates 
of only 20-30% in infants20, 23-25. 
 The most common genetic abnormality associated with the MLL gene is an in-
frame, chromosomal translocation which results in a chimeric protein expressing the 
amino-terminal end of the MLL protein fused to the carboxy-terminus of a partner 
protein26-28.  To date, over sixty different fusion partners have been identified in MLL 
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leukemia cases28.  The type of MLL-associated leukemia that develops depends in part on 
the particular fusion partner involved in the MLL oncoprotein.  Table 1 shows the 
incidence of the most common fusion partners and the associated leukemia phenotype.  
Internal duplication of various exons of MLL can also lead to the development of 
leukemia29-31.  In these instances, a separate partner protein is not fused to the 
oncoprotein; instead, specific functional domains of the MLL protein, including the 
CXXC domain, are duplicated to alter normal function.  These genetic aberrations of the 
MLL gene disrupt normal hematopoiesis causing the bone marrow to become 
overwhelmed with the production of immature leukemic cells.  These rapidly 
proliferating cells crowd out the production of normal blood cells leading to anemia, 
bleeding disorders, and potentially to an increased susceptibility to infection.  Eventually, 
this uncontrolled production of undifferentiated blast cells develops into end-organ 
failure and, ultimately, death in patients if the aggressive leukemia is not effectively 
treated. 
Table 1.  Occurrence of common genetic abnormalities involving MLL. 
 Genetic Alteration Resultant Oncoprotein Incidence 
A
M
L2
6,
28
,3
2-
33
 
t(9;11)(p22;q23) MLL-AF9/MLLT3 36% 
t(10;11)(p12q23) MLL-AF10/MLLT10 13% 
PTD (amplification of internal domains within MLL) 10% 
t(6;11)(q27;q23) MLL-AF6/MLLT4 9% 
t(11;19)(q23;p13.1) MLL-ELL 8% 
t(11;19)(q23;p13.3) MLL-ENL/MLLT1 8% 
Other i.e. MLL-AF1q/MLLT11, MLL-AF17/MLLT6 15% 
A
LL
21
,2
8,
32
 
t(4;11)(q21;q23) MLL-AF4/AFF1 56% 
t(11;19)(q23;p13.3) MLL-ENL/MLLT1 16% 
t(9;11)(p22;q23) MLL-AF9/MLLT3 10% 
t(10;11)(p12q23) MLL-AF10/MLLT10 3% 
PTD (amplification of internal domains within MLL) < 1% 
Other i.e. MLL-AF6/MLLT4, MLL-EPS15/AF1P 15% 
PTD: Partial Tandem Duplication 
8 
Hematopoiesis 
 MLL is involved in the normal process of hematopoiesis through the regulation of 
specific target genes (i.e. Hox cluster genes discussed later) which can also give rise to 
forms of acute leukemia when the expression of these target genes becomes misregulated.  
Hematopoiesis is the process by which the mature cells of the blood system develop from 
a series of immature, precursor cells (Figure 1).  The hematopoietic stem cell (HSC) is 
the precursor cell from which all subsequent hematopoietic cells originate.  HSCs are 
distinguished by the unique properties of all adult stem cells: long-term self-renewal 
which allows for the lifelong repopulation of the blood cells and pluripotency which 
enables HSCs to give rise to all cell types of the blood system including myeloid, 
lymphoid, and erythroid/megakaryocyte lineages.  HSCs are identified by the presence or 
absence of specific cell surface markers (for mouse: c-kit+, Sca1+, Lin-, Flk2-, CD34-, and 
Slamf1+; and for human: CD34+, Lin-, CD38-, CD90+, and CD45RA-)34. 
 When stimulated to divide, an HSC can undergo asymmetrical division resulting 
in two different cell types: one cell exhibiting the characteristics of an HSC that 
maintains the existing HSC pool and one daughter cell that can undergo maturation into a 
multipotent HSC with limited short-term repopulating capacity.  This short-term HSC 
then gives rise to common erythroid, myeloid, and/or lymphoid progenitor cells that 
express a unique set of cell surface markers which distinguish the various cell lineages.  
Eventually, these progenitor cells decrease the expression of immature cell-surface 
markers (i.e. c-kit+) and differentiate into erythroid (red blood cells or platelet-producing 
megakaryocytes), myeloid (neutrophils, monocytes/macrophages, eosinophils, and 
basophil cells), or lymphoid (natural killer cells and B or T lymphocytes) cells.  The  
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Figure 1.  Hematopoiesis diagram.
Long-term Hematopoietic
Stem Cell (HSC)
Short-term HSC
Self-Renewal Multipotency
Self-renewal
HOX genes
c-kit+
Lineage-
Specific
marks
Differentiation
The process by which undifferentiated hematopoietic stem cells (HSCs) give rise 
to all types of fully-differentiated blood cells.  (Cells of the erythroid lineage—
red blood cells and platelet-producing megakaryocytes—have been omitted from 
this diagram for simplicity.)
Common myeloid progenitor Common lymphoid progenitor
Myeloblast
Small lymphocyte
T lymphocyte B lymphocyteBasophil Neutrophil Eosinophil Monocyte
 
 
 
10 
differentiated blood cells are released from the bone marrow to circulate throughout the 
body or to travel to distant lymphoid tissues like the spleen, thymus, and lymph nodes 
where they function as mature cells or (in the case of lymphocytes) undergo further 
maturation. 
The hematopoietic stem cell niche 
 The environment in which the blood cells develop influences hematopoiesis.  
Extracellular factors from this environment can stimulate hematopoietic cells to 
proliferate, differentiate, or mobilize through various signaling mechanisms.  During 
embryonic development, hematopoiesis takes place in different locations as the fetus 
generates new tissues capable of cultivating the blood cells.  Initially, hematopoiesis 
takes place in blood islands of the yolk sac surrounding the developing embryo before 
moving to the aortic-gonadal-mesonephric region.  Once the tissues of the liver have 
developed, blood cell development moves to the fetal liver and finally to the bone 
marrow where hematopoiesis continues throughout adulthood35.  In each of these 
locations, the maturing hematopoietic cells require a particular set of conditions that 
make up a micoenvironment called the HSC niche. 
 The primary location for hematopoiesis in newborns and adults is the bone 
marrow found within the medullary cavities of long bones and the cancellous tissues of 
the skull, pelvis, and vertebrae.  The marrow has a distinct architecture consisting of a 
fibrous network and stromal cells which support the hematopoietic cells.  The HSCs are 
found deep within the marrow cavities in the periendosteal region where they are in 
contact with osteoblasts which line the bone surfaces.  Contacts made between these cells 
regulate signaling through N-cadherin and Notch1 and are critical for the retention of 
11 
HSCs in the niche and the maintenance of their pluripotent potential36-38.  Interspersed 
throughout the marrow are supportive stromal cells.  These cells secrete soluble factors 
like G-CSF, GM-CSF, SCF (also known as kit ligand), IL-6, and CXCL12 which are 
known to regulate proliferation, differentiation, and mobilization of hematopoietic cells39-
42
.  Nitric oxide (NO) from stromal cells has also been shown to modulate hematopoiesis 
and the mobilization of progenitor cells43-45. 
 Other factors like oxygen availability affect the cells within the HSC niche, and I 
hypothesized that oxygen levels may also affect MLL function during leukemogenesis46, 
47
.  Sinusoidal capillaries weave throughout the marrow to supply oxygen and nutrients to 
the niche and to remove metabolic byproducts.  The partial pressure of oxygen from 
gross marrow aspirates from superior iliac crests of healthy donors has been measured to 
be 55 mm Hg in one report (or about 7% compared to 21% O2 in typical ambient air of 
cell-culture incubators)48. Given the three-dimensional architecture and cellular 
complexity of the bone marrow, however, it is reasonable to envision microenvironments 
within the marrow in which there are variable levels of oxygen.  The stroma surrounding 
the sinusoidal capillaries form layers in which hematopoietic cells found further away 
from the capillary would be exposed to lower levels of oxygen as the oxygen diffuses 
away from the vessel and is depleted by other intervening, metabolically active cells. In 
fact, the oxygen levels in bone marrow have been mathematically modeled to 
demonstrate that a range of oxygen pressures likely exists in the marrow given the 
presence of intervening acellular fibers, single cells, or colonies of proliferating cells that 
separate hematopoietic cells from the sinusoidal capillaries49, 50.  These models suggest 
that the less mature, progenitor cells are positioned in the regions with lowest oxygen 
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tensions (<1% O2) while the more differentiated cells would be found closer to the 
capillaries with higher oxygen levels (6-7% O2). 
 This association between regional oxygen levels in the bone marrow and the 
distribution of hematopoietic cells has since been determined in vivo using mice that have 
been administered fluorescent Hoechst 33342 (Ho) dye to measure diffusion within the 
marrow cavities51.  The authors found HSCs to be enriched in the regions with the lowest 
perfusion of Ho dye suggesting that oxygen would be less available to these cells.  In 
fact, treatment with the hypoxia marker, pimonidazole, showed selective targeting of 
progenitor cells which were residing in the regions of least perfusion compared to the 
more mature hematopoietic cells within areas of greater perfusion.  These observations 
suggest that the hematopoietic cells are distributed in an organized manner within the 
marrow which corresponds to the oxygen availability within the HSC microenvironment.  
Subsequent studies in vivo have also confirmed that the hematopoietic precursor cells lie 
in regions with low oxygen tension while cells that are more actively proliferating in the 
presence of growth factors are positioned near the capillary sinuses of the marrow37, 52.  
The effect of low oxygen tension on hematopoietic cells has been measured in vitro.  
Progenitor cells grown in culture under hypoxic conditions (1% O2) have shown 
increased proliferation potential and increased colony forming ability53-55.  These findings 
suggest that a hypoxic bone marrow environment may be an advantageous environment 
for undifferentiated hematopoietic cells where they can maintain a self-renewing pool of 
stem cells56. 
 The hypoxic niche, however, has also been shown to benefit leukemic stem cells 
which rely on similar niche properties for continuous proliferation and evasion of 
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therapeutic treatments57-61.  With a conserved cysteine residue within the critical CXXC 
DNA-binding domain (described in detail below), I hypothesized that the hypoxic niche 
would benefit leukemia cells expressing an MLL fusion protein.  Under conditions of 
hypoxia, this cysteine—with a sulfhydryl side chain susceptible to post-translational 
modification—could be more readily kept in a reduced state which would allow the 
fusion protein to bind to its DNA targets and subsequently maintain gene expression and 
the undifferentiated cell state.  In contrast, exposure to higher levels of oxygen could 
potentially lead to oxidation of the thiol side chain that would disrupt MLL’s ability to 
bind to DNA causing the cells to decrease proliferation and undergo differentiation.   
HOX cluster genes and MLL 
 During hematopoiesis, a specific set of gene regulatory events occur that allow a 
cell to progress from a pluripotent HSC to a fully-differentiated blood cell of a particular 
lineage.  One set of highly regulated genes called the HOX cluster genes were first 
implicated in the process of hematopoiesis when progenitor cells were found to display 
unique expression patterns of subsets of HOX genes: the expression of HOX genes was 
decreased when cells underwent differentiation toward erythroid or myeloid lineages62.  
The name of the HOX genes is derived from a conserved DNA-binding domain (the 
homeobox domain) found in homeotic proteins which were first implicated in Drosophila 
development63.  Groups of multiple HOX genes form gene clusters that have been found 
to be evolutionarily conserved in metazoans from the fruit fly to chickens and humans 
suggesting that this set of homeobox-containing genes plays a critical role during 
development64, 65.  Subsequent studies in mice and humans confirmed the developmental 
role of HOX genes (Hox in mice) in embryonic patterning where differential expression  
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Figure 2 . The HOX genes are an evolutionarily conserved set of genes 
involved in development and hematopoiesis. 
The HOX cluster genes are conserved throughout evolution from fruit flies 
(Drosophila melanogastor) to humans and are organized in a pattern which 
corresponds to their role in the determination of segmental identity during 
development. (This figure was reproduced from the book Your Inner Fish by Neil 
Shubin with permission from the illustrator, Kalliopi Monoyios, University of 
Chicago).73
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of various HOX family members in spinal tissue corresponds to the determination of 
segmental identity66-68.  Differential expression of these homeobox-containing genes from 
flies to humans helps to establish polarity in the embryo so that an anterior-posterior 
orientation can develop along the central axis69, 70.  The spatial orientation of these genes 
closely corresponds with their role in determining segmental identity, and this gene 
structure has been evolutionarily conserved in eukaryotes from invertebrates to 
vertebrates (Figure 2)71-73.  In contrast to invertebrates which have homebox genes 
arranged linearly in a single cluster, the 39 HOX genes in humans are organized in four 
distinct clusters—HOXA, HOXB, HOXC, and HOXD—each containing 9-11 HOX genes.  
This clustered arrangement allows each subset of genes to be under the same 
transcriptional regulatory control for coordinated, temporospatial expression74, 75. 
 A critical role for MLL in Hox cluster gene regulation was demonstrated in 
heterozygous Mll +/-  and null Mll -/- mice12.  Mll -/- mice are embryonic lethal by day 
E10.5 while the heterozygous mutants survive through birth with defects in axial skeletal 
formation associated with the misexpression of Hoxa7 and Hoxc8 compared to wild type 
Mll +/+ mice.  These defects demonstrate haploinsufficiency (Mll +/- mice with loss of a 
single allele exhibited phenotypic defects) and indicate an important role for MLL in the 
regulation of Hox genes during development.  Furthermore, heterozygous Mll +/- mice 
showed decreased levels of erythrocytes, hemoglobin, and platelets suggesting the loss of 
Mll also impairs hematopoiesis12.  It was subsequently shown that loss of both Mll alleles 
prevents the sustained expression of Hox genes leading to the observed developmental 
defects and impaired embryonic hematopoiesis in both the yolk sac and fetal liver76-78.   
More recent findings using a loss-of-function mutant have confirmed the role of MLL in 
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adult hematopoiesis in which postnatal mice are unable to sustain normal blood cell 
development beyond three weeks following targeted gene excision79, 80.  Taken together, 
these findings show that MLL plays an important role in maintaining the proper 
temporospatial regulation of Hox cluster genes that is required during both embryonic 
development and during fetal and adult hematopoiesis.  
 The HOXA9 gene is a well-studied HOX cluster gene with regard to its role in 
hematopoiesis and MLL leukemia.   The initial association between HOXA cluster genes 
and hematopoiesis was suggested from observations that undifferentiated progenitor cells 
show higher HOXA cluster gene expression levels than more mature hematopoietic 
cells81.  Subsequent studies demonstrated a role for HOXA9 in the transformation of 
myeloid cells through a t(7;11)(p15;p15) translocation which generates a leukemogenic 
NUP98-HOXA9 fusion transcript and through the cooperation of MEIS1 with HOXA982-
84
.  Together Hoxa9 and Meis1 function as a heterodimeric transcription factor to bind to 
DNA targets through the homeobox domain.  The functional significance of this 
cooperativity has been verified in vivo through the transplantation of primary bone 
marrow cells that overexpress both Hoxa9 and Meis1.  These cells lead to overt leukemia 
in recipient mice within three months.  The role of Meis1 in MLL associated leukemia 
was further verified by knocking down Meis1 in MLL-AF9 transformed hematopoietic 
cells resulting in delayed leukemia progression in vivo85, 86. 
 The transformation of primary hematopoietic cells by MLL fusion proteins was 
shown to be mediated through upregulation of Hoxa cluster genes which subsequently 
cooperate with Meis187.  Specifically, a MLL oncoprotein is required for maintaining the 
expression of Hoxa7 and Hoxa9 in primary bone marrow cells to sustain immortalization 
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in vitro.  This critical role of MLL in HOX gene regulation was further demonstrated 
during embryoid body differentiation in which embryonic stem cells are stimulated in 
vitro to undergo coordinated differentiation to form hematopoietic progenitor cells 
followed by mature hematopoietic cells.  Mll null progenitor cells show marked reduction 
in Hoxa, Hoxb, and Hoxc cluster genes compared to Mll heterozygous cells during 
embryoid body differentiation88.  These Mll deficient embryoid body cells are capable of 
proliferating like the heterozygous counterparts but show reduced colony forming ability 
in vitro suggesting that positive regulation of Hox genes by Mll is necessary during the 
early stages of hematopoiesis in order to maintain the progenitor population from which 
the mature blood cells arise.  
The role of MLL in transcriptional regulation 
 Regulation of HOX gene expression is multifaceted involving large transcriptional 
complexes which can bind to multiple promoters within each cluster of genes, alternative 
splicing of the various gene transcripts, and regulation by microRNAs and long non-
coding transcripts75, 89, 90. The detailed mechanism by which MLL directly regulates the 
expression of HOX cluster genes is actively being studied and has been shown to involve 
multiple domains of the large MLL protein (431 kDa) (Figure 3A). 
 The MLL protein is a homolog of Drosophila trithorax and is a member of the 
SET (Suppressor of variegation, Enhancer of zeste, Trithorax) family of histone 
methyltransferases1, 91.  With the intrinsic enzymatic activity of its SET domain, MLL 
catalyzes trimethylation of lysine 4 on histone 3 (H3K4me3), a modification which is 
associated with active gene transcription92.  Interestingly, homozygous deletion of the 
exons encoding the SET domain from both Mll alleles leads to decreased H3K4  
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Figure 3.   Structural schematic of MLL, a MLL fusion, and MLL2 
proteins.
A
B
(A) The MLL protein is comprised of multiple functional domains. Leukemia-
causing fusion proteins necessarily retain the N-terminal domains of MLL including 
the menin-binding domain, AT hooks, and CXXC DNA-binding domain. The 
repression and transactivation domains of MLL are highlighted by red and green 
boxes, respectively.  The conserved Taspase I cleavage sites are indicated by 
arrowheads.
(B) MLL2 shares the same organization and types of functional domains as MLL. 
MLL2
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methylation in Hox promoters and decreased expression of several Hox genes; this 
deletion, however, does not recapitulate the embryonic lethality of the Mll null mice93.  
This finding suggests that the histone methyltransferase (HMT) activity of MLL’s SET 
domain helps to promote Hox gene activation but that the HMT activity is not the only 
function of MLL that contributes to gene regulation during development.  The ability of 
MLL to regulate HOX gene transcription during normal hematopoiesis or during 
misregulated leukemogenesis is also dependent on other functional domains of MLL and 
on MLL’s ability to localize to the nucleus2, 80, 94, 95. 
 MLL is proteolytically cleaved by Taspase I separating MLL into N- and C-
terminal fragments which associate through internal FYRC and FYRN domains and 
localize to the nucleus96, 97.  The N-terminal fragment of MLL can bind directly to DNA 
through several domains: a set of three AT hooks and a zinc-binding domain called the 
CXXC domain (discussed in detail below)3, 98.  These AT hook motifs recognize AT rich 
or bent regions of DNA, and the CXXC domain recognizes non-methylated CpG 
dinucleotides2, 3, 5, 11.  These DNA sequences recognized by MLL are relatively 
ubiquitous, so targeting of MLL to specific genes must occur through associations with 
other proteins that can provide greater specificity.  Interaction with menin (and the 
subsequent recruitment of lens epithelium-derived growth factor, LEDGF, a 
transcriptional co-regulator) and associations with E2F and host cell factor (HCF)-1 have 
been shown to help target MLL to specific regions of DNA and facilitate 
transformation99-104.  Through its interaction with menin, MLL functions in a larger 
complex consisting of Ash2L, WDR5, Rbbp5, Dpy30, and HCF to regulate gene 
transcription105.  The critical menin-binding and DNA-binding domains are found within 
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the N-terminal portion of MLL and are required for the leukemogenic activity of MLL 
fusion proteins which induce immortalization and subsequently cause leukemia (Figure 
3A)2, 4, 94.  
 MLL also contains a group of PHD finger domains which are commonly found in 
chromatin-associating proteins.  The third PHD finger of MLL binds to both H3K4me3 
histones and to the peptidyl-prolyl cis-trans isomerase Cyclophilin 33 (Cyp33) through 
the RNA-recognition motif (RRM) domain106-108.  Together these interactions help MLL 
regulate target Hox gene expression through the prolyl isomerization activity of Cyp33 
which decreases MLL’s ability to bind to the H3K4me3 mark on histone tails106, 109.   In 
MLL fusions, this third PHD finger is necessarily absent so that Cyp33 cannot be 
recruited to repress the transcriptional activation of target genes facilitated by the fusion 
protein110. 
 The CXXC domain of MLL is located within a larger region of MLL termed the 
repression domain (amino acids 1100-1400) (Figure 3A).  The repression domain was 
functionally named for its ability to suppress reporter gene expression in contrast to the 
activation domain in the C-terminus of MLL (residues 2340-3123) which showed 
increased expression in the same assay3.  Our lab has previously shown that the 
repression domain directly interacts with co-repressor proteins—histone deacetylases 1 
and 2 (HDACs 1 & 2), polycomb group proteins (HPC2 & BMI-1), and C-terminal-
binding protein (CtBP)—although the individual residues of MLL with which they 
interact have not yet been determined8.   HDACs 1 & 2 have enzymatic activity for 
removing acetyl groups from lysine residues on histone tails.  This restores a positive 
charge to the side chain of histone lysines and increases histone affinity for the negatively 
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charged phosphate backbone of the DNA to effectively maintain a closed, 
heterochromatin state. 
 The activating functions of MLL (a member of the Trithorax group of proteins) 
are opposed by the repressive functions of Polycomb group proteins111.  The interplay 
between Trithorax and Polycomb group (PcG) proteins provides tight regulation of gene 
expression that is necessary for proper segmental development in the embryo112.  In the 
adult, the balance between these two groups of activator and repressor complexes helps to 
maintain proper gene expression during hematopoiesis.  BMI-I and HPC2 are both 
members of the polycomb repressive complex 1 (PRC1) which recognizes the repressive 
H3K27me3 mark placed by the PRC2 complex113.  HPC2/CBX4 is the human polycomb 
group 2 protein that was first identified by Satijn et al. as a repressor protein with a 
highly conserved C-terminal binding domain114.  HPC2 functions as a core component of 
the Polycomb Repressive Complex 1 (PRC1) along with BMI-1, RING1, and 
polyhomeotic homolog (Ph) proteins.  With its distinct chromodomain, HPC2 recognizes 
and binds H3K27me3 marks that are catalyzed by EZH2 of the PRC2 complex and 
recruits RING1 (and subsequently, the rest of the PRC1 complex) through the C-terminal 
domain to repress transcription111, 114-116.  The polycomb group proteins function to 
establish and maintain a heterochromatic state that represses gene transcription.  CtBP 
can cooperate with PcG proteins to repress transcriptional activity through its direct 
interaction with HPC2117.  CtBP has been implicated in tumorigenesis through the 
repression of tumor suppressor genes118, 119. 
 In MLL-associated leukemia, however, the balanced transcriptional regulation of 
MLL target genes is disrupted by the fusion of a partner protein to MLL.  The N-terminus 
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of MLL is often fused to the C-terminal sequence of a protein, commonly a partner 
protein that is found in transcription elongation complexes28.  The recruitment of a fused 
transcriptional coactivator to MLL target genes is thought to cause uninhibited gene 
expression through the subsequent recruitment of factors which mediate transcriptional 
elongation120-122.  This gene activation through the fused partner protein overcomes the 
transient associations of the repressive PcG complexes leading to gene misregulation and 
ultimately leukemia123, 124. 
 The CXXC domain and ‘post CXXC’ residues of MLL were recently shown to 
interact with the coactivator Polymerase Associated Factor (PAF) protein9, 10.  PAF is a 
component of the PAF complex (PAFc) comprised of PAF1, RTF1, Ctr9, Leo1, and 
Cdc73 protein subunits which were identified through association with the COMPASS 
complex containing members of the Trithorax family125.  PAFc cooperates with 
elongating RNA polymerase II to enhance transcription and was shown to be necessary 
for introducing activating epigenetic marks (i.e. methylation of H3K4 and H3K79) during 
active gene transcription125-127.  In MLL fusions, the PAF1 subunit directly interacts with 
the residues flanking the CXXC domain and mutation within the CXXC domain can 
disrupt this interaction9, 10.  PAFc was shown in these studies to enhance Hox gene 
expression mediated by a MLL-AF9 fusion, and disruption of the PAF1 interaction 
resulted in decreased recruitment of the MLL fusion to Hox gene promoters, a subsequent 
decrease in Hox expression, and loss of transformation capacity in vitro. 
 MLL functions in the context of a large network of proteins that are associated 
with transcriptional activation and elongation, and association with Polycomb Group 
proteins helps to moderate the transcriptional activation of MLL target genes.  Within 
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these larger transcriptional complexes, wild type MLL functions to maintain active gene 
transcription through the HMT activity of the SET domain and by protecting 
unmethylated promoter regions of target genes via the CXXC domain further facilitating 
gene expression92, 128, 129.  In contrast, MLL fusions alter this carefully regulated 
transcription to cause overexpression of homeotic genes that maintain hematopoietic cells 
in an undifferentiated state.  It has recently been shown that the MLL-AF9 fusion protein 
requires a normal allele of MLL to maintain transcription of gene targets130.  Together the 
wild type MLL protein and the MLL fusion protein alter hematopoiesis by localizing to 
and driving increased expression of a subset of genes that are normally regulated by wild 
type MLL131, 132. 
MLL2 is the closest homolog of MLL 
 MLL (also known as MLL1) is the founding member of the MLL family of SET 
domain-containing H3K4 histone methyltransferases of which there are five members 
(numbered 1 to 5).  The closest homolog of MLL is MLL2, whose gene is located at 
chromosomal band 19q13.16.  (Note that MLL2 is officially named MLL4 by the Human 
Genome Organization Gene Nomenclature Committee, though, in the literature these 
names have been shared with a less homologous member of the MLL family known as 
ALR-1; MLL2—as I will refer to the closest homolog of MLL that was studied in this 
dissertation—has also less commonly been referred to as TRX2, HRX2, KMT2b, WBP7, 
and KIAA0304.)  While the MLL2 transcript is shorter than MLL (8.5 versus 12.5 kb), 
both genes are encoded by 37 exons and retain the same number and orientation of 
functional domains including the AT hooks, CXXC DNA-binding domain, PHD fingers, 
and SET domain (Figure 3B)6, 133.  The large MLL2 protein (290 kDa) is proteolytically 
24 
cleaved by Taspase I in the same manner as MLL134.  Together, these findings suggest 
that a gene duplication occurred in vertebrates and that the duplicated genes have 
subsequently evolved into the two closely related proteins MLL and MLL26. 
 Like MLL, MLL2 is ubiquitously expressed throughout the body6, 135.  However, 
MLL2 is not a functionally redundant paralog of MLL.  MLL and MLL2 knockout mice 
are both independently embryonic lethal with death by day E10.5 versus E11.5, 
respectively, suggesting that loss of one of these MLL family members cannot be 
compensated by the other136.  Embryos of Mll2 null mice show growth retardation, 
delayed differentiation, and increased cellular apoptosis136, 137.  Decreases in Hoxb1 and 
Mox1 expression were observed in somites surrounding the neural tube of Mll2 null 
embryos, reminiscent of the axial changes observed in development of Mll deficient 
embryos12, 136. 
 MLL2 associates with a similar transcriptional activation complex as MLL to 
regulate Hox gene transcription.  Like MLL, this complex includes menin, Ash2L, 
Rbbp5, WDR5, CpG binding protein (CGBP/CFP1), and Dpy30105, 138, 139.  Of 
importance, MLL and MLL2 do not co-exist simultaneously within the same purified 
transcriptional complexes, further confirming distinct roles for these two paralogs140.  In a 
study of global H3K4me3 patterns in mouse embryonic fibroblasts (MEFs), Mll -/- cells 
showed decreased H3K4me3 within the Hoxa and Hoxb cluster and no change in 
trimethylation within the Hoxd cluster129.  When menin was knocked out in MEFs, a 
decrease in trimethylation within the Hoxa and Hoxb loci was observed with a significant 
reduction of H3K4me3 within the Hoxd locus.  Since MLL and MLL2 both interact with 
menin during transcriptional regulation, it seems that H3K4 trimethylation within the 
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Hoxd locus does not depend on MLL (H3K4me3 persisted in Mll -/- mice) but instead is 
dependent on another histone methyltransferase—likely MLL2—which also requires 
menin for H3K4 trimethylation.  Other studies looking at the effects of the loss of Mll2 at 
specific loci have shown decreased expression of Hoxb1, -2, and -5  and Mox1 (with 
unaffected Hoxa1 expression) and decreased H3K4me3 in the promoter regions of Bcl2 
and Magoh2136, 137, 141.  Broader screening for MLL2 target genes has yet to be conducted 
to better understand how the role of MLL2 is distinct from that of MLL.  It is also not 
known whether MLL2 interacts with the same co-repressor proteins that were previously 
identified by our lab to interact with the MLL repression domain (HDAC1/2, HPC2, 
BMI-1, and CtBP)8.  The first aim of my dissertation was to determine if these 
interactions are also conserved between these two homologs. 
 Given the structural and functional similarities between MLL and MLL2, it is 
intriguing that only two reports to date have suggested involvement of MLL2 in 
tumorigenesis133, 142.  Several solid tumor types have shown gene amplification of MLL2 
(pancreatic or glioblastoma cell lines) or overexpression of MLL2 protein (invasive 
breast and colon cancer cell lines) compared to normal tissue.   Interestingly, MLL2 
translocations have not yet been found in leukemia.  When expressed by retrovirus, an 
experimentally derived MLL2-ENL fusion containing the same critical N-terminal 
domains found in MLL fusions (Menin-binding domain, AT hooks, and CXXC domain) 
was unable to transform primary hematopoietic cells in vitro7.  Transformation capacity 
of these cells could be rescued by the chimeric fusion protein only when sequences that 
included the MLL CXXC domain were introduced in place of the MLL2 sequence (MLL 
residues 1050/1149 to 1337).  This finding suggests that there are specific differences in 
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amino acids within the CXXC domains of MLL and MLL2 that alter the ability of the 
fusion proteins to transform hematopoietic cells.  The first aim of my dissertation focuses 
on these specific amino acid differences between the CXXC domains of MLL and MLL2 
to determine which, if any, of the residue differences contribute to the leukemogenic 
capacity of MLL fusion proteins.  
The MLL CXXC Domain 
 The CXXC DNA-binding domain of MLL was first identified as a region having 
homology to a domain found in DNA methyltransferases98.  This domain is found in the 
N-terminus of both MLL and MLL2 and shown to bind to unmethylated CpG 
dinucleotides2, 5, 11.  This domain is necessarily retained in MLL fusion proteins that have 
the capacity to generate leukemia and helps to maintain active expression of target Hox 
genes by preventing repressive promoter methylation2, 5, 11, 128.  The CXXC domain is 
named for the spacing of eight cysteine residues within this domain which coordinate two 
zinc molecules (Figures 4 and 5).  The spacing of these cysteines is conserved across 
MLL homologs of vertebrate and invertebrate species and also found in MLL2 and other 
mammalian proteins.  Four cysteines each coordinate one zinc ion through their reduced, 
sulfhydryl sidechains to generate a stable, tetrahedral Zn-binding motif.  This motif varies 
from a classical Zn-finger structure in that the coordinating cysteine residues are not 
sequentially organized (Figures 4A and 5B)11, 143. 
The CXXC domain is a crescent-shaped structure in which the interior surface 
forms direct interactions with its target DNA (Figure 5).  This domain preferentially 
binds to non-methylated CpG DNA sequences through electrostatic interactions and 
hydrogen bonding5, 11.  The CXXC domain is essential for in vitro transformation of cells  
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 Figure 4. The MLL CXXC domain is conserved across species, and 
similar domains are found within other proteins.
B
(A) Sequence alignments of MLL CXXC domains from various eukaryotes and 
other CXXC-domain containing proteins showing highly-conserved spacing of 
zinc-coordinating cysteines (yellow) and the non-zinc-coordinating cysteines
aligning with Cys1188 of hMLL (red).  The coordination of the first (1) and 
second (2) zinc ions by the conserved cysteine residues is indicated below.  
(Alignments courtesy of Manuel Diaz, MD, Loyola University Chicago.)
(B) Phylogenetic tree showing the homology between various mammalian 
CXXC domains (reproduced from Figure 1C of Frauer et al.144).
A
 
 
28 
Figure 5.  Comparison of the MLL and MLL2 CXXC domains.
A
B C
(A) Sequence alignment of the MLL (aa1147-1203) and MLL2 (aa958-1014) 
CXXC domains highlighting zinc-coordinating cysteines in yellow, Cys1188 of 
MLL in red, and non-conserved residues of interest in blue. (B) Solved solution 
structure of the MLL CXXC domain (green ribbon) in complex with DNA (ball 
and stick) from PDB ID 2KKF. (C) Threaded model of the MLL2 CXXC domain 
based on the solved MLL structure. (D) Amino acids that were selected to study in 
Aim 1 by introducing the MLL residue into the MLL2 CXXC domain.
GKKMRMARCGHCRGCLRVQDCGSCVNCLDKPKFGGPNTKKQCCVYRKCDKIEARKME
KKGRRSRRCGQCPGCQVPEDCGVCTNCLDKPKFGGRNIKKQCCKMRKCQNLQWMPSKaa1147
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expressing the MLL-ENL fusion protein2.  Mutation in any of the eight, Zn-coordinating 
residues inhibits oncogenic capacity of these cells due to destabilization of the protein 
structure and loss of DNA binding2, 143.  Based on the NMR structure of this domain 
solved both in the presence and absence of CpG-containing DNA, Laurie Risner, PhD, in 
our lab has recently introduced point mutations into the MLL CXXC domain which do 
not disrupt folding of the domain11.  When mutations of the MLL-AF9 CXXC domain 
were introduced into residues that directly interacted with DNA (R1154A, K1185A, 
Q1187A), a decrease in DNA-binding affinity was observed compared to the wild type 
MLL CXXC domain in conjunction with a loss of in vitro transformation capacity of 
these mutant MLL-AF9 fusions in colony forming assays.  This evidence demonstrates 
that MLL fusion proteins require the DNA binding capacity of the CXXC domain for the 
development of acute leukemia. 
There is one cysteine residue—Cysteine 1188—in the MLL CXXC domain which 
does not coordinate with the zinc molecules (highlighted in red in Figures 4-6).  It is 
located adjacent to a conserved, Zn-coordinating cysteine (Cys1189) and is critically 
positioned on the surface of the DNA-binding interface11.  The thiol group of a cysteine 
side chain is particularly susceptible to biochemical changes via redox reactions and post-
translational modification13.  Much research has been reported on the regulation of 
transcription factor binding to DNA13, 145-150.  In many instances, this regulation occurs at 
sites of cysteine residues within a Zn-coordinating structure.  Zinc-binding motifs 
containing a zinc ion tetrahedrally coordinated to cysteine or histidine groups are 
relatively common within DNA-binding proteins including SP1, NF-κB, p53, TFIIH, 
estrogen receptor, and estrogen related receptor-2 (ERR-2)13.  The functions of such 
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transcription factors have been subject to modulation by redox reactions as determined by 
site-directed mutagenesis studies and treatments with oxidizing or reducing agents 
leading to altered DNA-binding affinity or altered target gene expression13, 147, 151.  The 
DNA-binding domains of p53, TFIIH p44, and ERR-2 all contain an additional cysteine 
residue which does not coordinate zinc and physiologically modulate protein binding to 
DNA to function as a molecular switch152-154. 
The non-Zn-coordinating cysteine of the MLL CXXC domain, Cys1188, is 
conserved in the MLL orthologs of vertebrates but is noticeably absent in more distant, 
invertebrate species (Figure 4A).  Interestingly, epigenetic regulatory mechanisms (i.e. 
those involved with methylation of gene promoters) have simultaneously diverged during 
eukaryotic evolution155-158.  These parallel evolutionary phenomena support the 
hypothesis that Cys1188 in the CXXC domain of MLL may be functioning as a 
molecular switch to regulate the binding of CXXC to its HOX gene targets. 
Cysteine 1188 does not directly interact with DNA through hydrogen bonds or 
salt bridges but is located on the DNA-binding surface of the MLL CXXC domain11.  
When this residue was mutated to alanine (C1188A), the transduced MLL-AF9 construct 
was able to immortalize hematopoietic progenitor cells with efficiency similar to wild 
type MLL-AF9 in a colony formation assay11.  The DNA-binding affinity was also found 
to be equal to that of the wild type CXXC domain.  In contrast, when this Cys1188 
residue was mutated to aspartate (C1188D), a repulsive negative charge was introduced 
into the domain which disrupted DNA binding resulting in a loss of colony forming 
ability, even though the domain retained appropriate folding.  In vivo transplantation of 
bone marrow cells expressing MLL(C1188A)-AF9 or MLL(C1188D)-AF9 into mice 
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confirmed the in vitro results showing that functional binding of the MLL CXXC domain 
to DNA is required for the development of leukemia.  Of note, mutation of Cys1188 to 
inert alanine (which is not susceptible to regulation by post-translational modifications) 
led to a shorter latency of leukemia development compared to the wild type Cys1188 
(median survival of about 40 versus 90 days)11.  With a critical position on the DNA-
binding surface and a sulfhydryl side group susceptible to post-translation modification, 
this Cys1188 residue may serve a functional role within the MLL CXXC domain to 
regulate MLL’s binding to HOX gene targets. 
This non-zinc-coordinating cysteine residue is conserved in the MLL2 CXXC 
domain.  There are, however, a number of other amino acids which differ between MLL 
and MLL2 within the CXXC domain (Figure 5).  The goal of the first aim of my 
dissertation was to study the functional differences between the residues of the MLL2 
CXXC domain and those of the MLL CXXC domain to understand how specific residues 
of MLL contribute to leukemia.  Based on the alignments of the MLL and MLL2 CXXC 
domains (Figure 5A), the solved CXXC domain structure of MLL (Figure 5B), and the 
threaded model of the MLL2 CXXC domain (Figure 5C), strategic amino acid 
substitutions were introduced into the MLL2 CXXC domain (Figure 5D).  Eleven of the 
thirteen substitutions that were studied are positioned between the conserved cysteine 
residues which coordinate the zinc ions.  Since the structural cysteine residues allow the 
MLL CXXC domain to form a stable domain, I predicted that these non-conserved 
residues of the MLL2 CXXC domain would be found in a similar position within the 
MLL2 CXXC domain yet alter the overall DNA- or protein-binding function(s) of the 
domain.  Two additional amino acid substitutions of the CXXC domains that were also  
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Figure 6. Comparison of amino acid differences within the MLL 
and MLL2 CXXC domains to be studied in Aim 1.
90°
Four surfaces of the MLL CXXC domain colored according to the sequence 
alignment above in which blue residues represent amino acid substitutions that 
were introduced into the MLL2 CXXC domain to restore the residue(s) to the MLL 
sequence.
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studied (A964R and R1011M) are positioned outside of the boundaries defined by the 
conserved, structural cysteines.  These residues are found in close proximity to one 
another within the MLL CXXC domain and near the DNA.  They were predicted to alter 
DNA-binding affinity, so these substitutions were also introduced into the MLL2 CXXC 
domain for studying their contribution to MLL function.  The specific amino acid 
differences that were studied in my dissertation are highlighted in blue on the structural 
model of the MLL CXXC domain in Figure 6.  I predicted that amino acid differences 
between the MLL and MLL2 CXXC domains would contribute to variable DNA-binding 
affinities or to variable interactions with other cofactor proteins depending on the location 
of the specific residues within the CXXC domain.  Amino acid substitutions on the 
interior surface of the domain may alter DNA-binding affinity.  In contrast, substitutions 
on the outer surface of the domain may alter binding of cofactor proteins to affect overall 
function of the fusion protein or may indirectly contribute to altered CXXC DNA-binding 
affinity through allosteric effects.  The goal of my first project aim was to explore how 
specific amino acid differences between the MLL and MLL2 CXXC domains affect the 
critical functioning of the CXXC domain and alter the transformation capacity of 
leukemogenic fusion proteins. 
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CHAPTER 3 
 
METHODS 
 
Cloning of MLL/MLL2-AF9 fusion constructs for in vitro colony assay 
 
 The wild type MLL2 CXXC domain was PCR amplified from a pcDNA4-His-
MaxB plasmid containing the entire exons 1-37 of MLL2 (NCBI Accession Number 
NM_014727, courtesy of Kevin FitzGerald, S.J., PhD, Georgetown University) using a 
high-fidelity, cloned Pfu DNA polymerase (Stratagene, #600159) and using primers with 
AatII and BamHI restriction sites on the ends of the forward and reverse primers (Table 
2, A).  (Priming sites of cloning primers are depicted in Table 2, and the primer 
sequences are listed in Table 3.)  The blunt end PCR product consisting of the MLL2 
CXXC domain (nucleotides 2872-3042) with the flanking restriction sites was ligated 
into a pCR-Blunt holding vector in a 10µL reaction volume for 1 hour at 16°C using T4 
DNA Ligase (Fermentas, #EL0014).  1µL of the ligation reaction mixture was 
transformed into 50µL of chemically competent OneShot® Top10 Competent E.coli cells 
according to the Zero Blunt® PCR Cloning Kit protocol (Invitrogen, #K2750; #C4040).  
The accuracy of the MLL2 CXXC insert was verified by DNA sequencing (ACGT, Inc., 
Wheeling, IL) using the M13R primer (Table 2, B; sequencing primers and priming sites 
are indicated in gray).  The pCR-Blunt-MLL2-CXXC construct was purified using the 
GeneJETTM Plasmid Miniprep Kit (Fermentas, #K0503) as were all subsequent plasmids 
used in the cloning of the fusion constructs.  All plasmid concentrations following
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Table 3. MLL and MLL2 cloning and sequencing primers 
Cloning Primers 
Amplicon Primers (5’ to 3’) 
MLL2 CXXC For: GGG ACG TCG AGG CAA GAA GAT GCG CAT GGC TCG ATG Rev: GGG GAT CCT TCC ATC TTC CGA GCC TCT ATT TTG TC 
MLL2 ‘post-CXXC’ For: GGG GAT CCC GAC TGG CTA AAA AAG GCC GG Rev: GGG TCG ACA CGG ACG CGG TGC ACA CC 
MLL RD For: GGT CGC GAG AAC GAG AAA AGA TTT TGT CTT CC Rev: GGG TCG ACT CTG ATC CTG TGG ACT CC 
MLL 1/2 RD For: GGT CGC GAG AAC GAG AAA AGA TTT TGT CTT CC Rev: GGG TCG ACA CGG ACG CGG TGC ACA CC 
Sequencing Primers 
Amplicon Primers (5’ to 3’) 
M13R (universal) GGA AAC AGC TAT GAC CAT G 
MLL 1119F CAG AAG ATG CTG AAC CTC TTG CTC C 
AF9 Rev GGG TCG ACA CGG ACG CGG TGC ACA CC 
T7 Term (universal) GCT AGT TAT TGC TCA GCG G 
 
miniprep isolation were determined using 2µL of eluted plasmid DNA with a NanoDrop 
2000 (Thermo Scientific) prior to submitting sample(s) for sequencing or prior to 
subsequent digestion. 
A novel construct encoding the N-terminal fragment of MLL (nucleotides 1-4212) 
was previously generated by Laurie Risner, PhD.  This construct contains 5’-AatII and 
3’-BamHI restriction sites flanking the nucleotide sequence encoding the MLL CXXC 
domain for conveniently swapping in mutant or alternative sequences (while still 
maintaining the original reading frame of MLL: NCBI Accession Number L04284)11 
(Table 2, D).   This 5’-fragment of MLL (pMCS5 vector) and the sequence encoding the 
MLL2 CXXC domain (pCR-Blunt vector) were subjected to double digestion with AatII 
(New England Biolabs, NEB) and BamHI (NEB) restriction enzymes in 40µL reaction 
volumes at 37°C for 1-2 hours in NEB Buffer #4 to release the respective sequence 
encoding the CXXC domains from the vectors.   Both reactions were heat inactivated at 
65°C for 15 minutes.  Calf intestinal alkaline phosphatase, CIP (NEB, #MO290S), was 
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added to the digested pMCS5 vector containing the digested 5’-MLL fragment (35 
minute incubation at 37°C) to prevent self-ligation of the vector by removing the terminal 
5’-phosphate.  The digestion products were then separated by electrophoresis on a 1% 
agarose gel or a 4% NuSieve® 3:1Agarose (BiWhittaker Molecular Analysis—BMA, 
#50090) gel at 90V for 30min.  The respective bands were gel purified with the Qiaex® 
II Gel Extraction Kit (Qiagen, #20051) and ligated together for 2 hours at 14°C to create 
a 5’ construct encoding the chimeric MLL/MLL2(CXXC) domain (Table 2, E).  5µL of 
the ligation reaction mixture was used to transform 50µL of chemically competent DH5α 
E.coli cells according to supplier’s protocol (NEB, #C2988J).  This construct was 
sequenced with the MLL 1119F primer which anneals at MLL nucleotide 3355 just 
upstream of sequence encoding the CXXC domain to ensure that the swap of the MLL 
and MLL2 sequences was successful and to ensure that the correct reading frame was 
maintained through the restriction sites. 
The ‘post-CXXC’ region of MLL2 (nucleotides 3043-3522) was cloned from the 
full length MLL2 construct using high fidelity PCR amplification as described above, this 
time, with forward and reverse primers containing BamHI and SalI restriction sites, 
respectively (Table 2, A).  The blunt PCR product was ligated into a pCR-Blunt vector 
and transformed into Top10® chemically competent E.coli as described above.  The 
insert was sequenced to verify its accuracy using the M13R primer (Table 2, C). 
To exchange the ‘post-CXXC’ region of MLL and MLL2, the chimeric pMCS5-
5’ MLL/MLL2(CXXC) construct and the pCR-Blunt-MLL2 ‘post-CXXC’ constructs 
were doubly digested with BamHI (NEB) and SalI (NEB) in the same reaction conditions 
as above and the products were separated on a 1% agarose or 4% NuSieve® 3:1Agarose 
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gel by electrophoresis (90V for 30min).  The appropriate fragments were then gel 
purified and ligated at 14°C  for 4 hours to form the pMCS5-5’ MLL/MLL2(CXXC + 
‘post-CXXC’) construct (Table 2, F).  2µL of the ligation mixture was used to transform 
50µL of DH5α E.coli cells (NEB).  The plasmid DNA was purified, and the insert 
accuracy was verified by sequencing with the MLL 1119F primer. 
The wild type fusion construct, pMSCVneo-MLL-AF9, was previously cloned in 
our lab by Laurie Risner, PhD.  This construct was used for subsequent studies as the 
highly-transforming, positive control and also served as the source of the 300-bp AF9 
fusion partner for the MLL/MLL2 constructs (Table 2, G).  The 3’-end of AF9 (NCBI 
Accession Number AK301474)—which is fused to a sequence encoding a FLAG tag at 
the 3’ end—was digested from the pMSCV-MLL-AF9 with SalI (Promega) and BglII 
(NEB) in a 30µL reaction volume with Buffer H (Pharmacia) overnight at 37°C.  This 
digestion reaction was heat inactivated as done previously, the products separated by 
electrophoresis on a 2% agarose gel (90V for 45 minutes), and gel purified for use in a 
three-way ligation reaction. 
The empty vector, pMSCVneo (used for retroviral expression in mammalian 
packaging cells), was linearized by double digestion with EcoRI (Gibco) and BglII 
(NEB) in a 20µL reaction volume with Buffer H (Pharmacia) overnight at 37°C.  This 
digestion reaction was heat inactivated and treated with CIP as before to prevent self-
ligation of the vector.  The linearized plasmid was purified through electrophoresis and 
gel extraction.  The 5-’MLL/MLL2(CXXC ± ‘post-CXXC’) nucleotide sequence was 
released from the pMCS5 vector by digestion with EcoRI (Gibco) and SalI (Invitrogen) 
in a 50µL reaction volume with Buffer H (Pharmacia) for 2-3 hours at 37°C.  The 
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digestion products were purified by gel extraction following electrophoresis on a 0.8% 
agarose gel for 45 minutes for optimal separation between the 4.2 kb insert and the ~3kb 
plasmid (Table 2, E & F). 
To complete the cloning of the final fusion constructs, a three-way ligation 
reaction was conducted in which the EcoRI/BglII-linearzied pMSCVneo plasmid (6.5kb), 
the SalI/BglII-digested fragment of AF9 (300bp), and one of the EcoRI/SalI-digested 5’-
MLL/MLL2(CXXC ± ‘post-CXXC’) fragments were combined in a 1:5:2 molar ratio 
with T4 DNA ligase (Fermentas) in a 10µL reaction volume overnight (nearly 24 hours) 
at 14°C.  1µL of three-way ligation mixture was added to 20µL of freshly thawed 
ElectroMAXTM DH5α-ETM E.coli cells (Invitrogen, #11319-019) while on ice.  This cell 
and ligation mixture was then transferred to a pre-chilled, disposable 
microelectroporation chamber (Whatman Biometra, #11608-031) within the Chamber 
Safe component for the Cell-Porator electroporation apparatus (Gibco BRL Life 
Technologies, #11604).  With the Voltage Booster set at 4kΩ and the Pulse Control / 
Power Supply set at 330kF capacitance, “Low Ω,” “Fast” charge rate, and switched to 
“Charge,” the voltage on the unit was increased above 310V.  The “Charge” switch was 
flipped to “Arm” allowing the voltage to decrease until exactly 310V was reached at 
which point the cells were stimulated with an electrical pulse by pressing the trigger 
button.  The electrically transformed cells were then transferred to 1mL of pre-warmed 
S.O.C. media, incubated for 1 hour at 37°C while shaking at 225rpm, and plated on LB 
agar with ampicillin (100µg/mL) selection overnight to allow transformed colonies to 
grow.  The few colonies that formed were picked from the plate and screened for the 
correct insert first by PCR amplification using Taq DNA Polymerase (GenScript, 
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#E00007) and secondly via bi-directional sequencing using the proximal MLL 1119F and 
distal AF9 Rev primers to ensure sequence coverage across all restriction site junctures of 
the large, 4.5kb fusion constructs (Table 2, H and I). 
All PCR reactions were performed using a PCR Express Thermal Cycler (Thermo 
Hybaid, #HBPX 110).  Agarose gel electrophoresis of constructs was conducted using the 
Sub-Cell® GT Agarose Gel Electrophoresis System (BioRad) and a low-voltage power 
supply (Thermo EC, #EC250-90).  All small-scale centrifugations were conducted in a 
benchtop Spectrafuge 16M (Labnet, #C0160), and ligation reactions were chilled in a 
benchtop MicroCooler IITM (Boekel, #260010). 
Generation of and cloning of mutant MLL2 CXXC domain constructs 
 
 Site-directed mutagenesis was performed on the isolated MLL2 CXXC domain 
within the pCR-Blunt plasmid (Table 2, B) using the QuickChange Site-Directed 
Mutagenesis Kit (Stratagene, #200518) in order to introduce residues of the MLL CXXC  
domain into the MLL2 CXXC domain.  Mutagenesis primers are listed in Table 4.  
Performing the mutagenesis reaction on the isolated domain was advantageous as the 
small insert size facilitated convenient sequence verification and ensured that unexpected 
mutations did not occur during the PCR amplification steps of the mutagenesis reaction.  
A high fidelity PfuTurbo DNA polymerase provided with the kit was used to ensure 
accuracy of the nucleotide substitution(s).  
The kit protocol was followed with some exceptions: 500ng of template pCR-
Blunt-MLL2 CXXC dsDNA was used for the PCR reactions (instead of the 
recommended 5-50ng); the elongation step was run for 4 minutes to allow extension of 
the full 3.7kb construct; and the PCR reaction was run for 14 cycles.  In the case of two 
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Table 4.  Site-directed mutagenesis primers used to introduce individual MLL 
residues into the MLL2 CXXC domain. 
Amino Acid 
Substitution 
(MLL2  MLL) 
Codon Conversion Primers (5’ to 3’) 
A964R GCT  CGT 
For:  GCA AGA AGA TGC GCA TGC GTC 
GAT GTG GAC ACT GTC 
Rev: GAC AGT GTC CAC ATC GAC GCA 
TGC GCA TCT TCT TGC 
H968Q CAC  CAG 
For: ATG GCT CGA TGT GGA CAG TGT 
CGG GGC 
Rev: GCC CCG ACA CTG TCC ACA TCG 
AGC CAT 
R970P CGG  CCG 
For: GTG GAC ACT GTC CGG GCT GCC 
TAC G 
Rev: CGT AGG CAG CCC GGA CAG TGT 
CCA C 
V975P GTG  CCG 
For: CGG GGC TGC CTA CGT CCG CAG 
GAC TGT G 
Rev: CAC AGT CCT GCG GAC GTA GGC 
AGC CCC G 
LRVQ973-
6QVPE 
CTA+CGT+GTG+CAG 
CAA+GTT+CCG+GAG 
For: GGA CAC TGT CGG GGC TGC CAA 
GTT CCG GAG GAC TGT GGG TCC 
TGT GT 
Rev: ACA CAG GAC CCA CAG TCC TCC 
GGA ACT TGG CAG CCC CGA CAG 
TGT CC 
V982T GTC  ACC 
For: AGG ACT GTG GGT CCT GTA CCA 
ACT GCC TAG ACA AGC 
Rev: GCT TGT CTA GGC AGT TGG TAC 
AGG ACC CAC AGT CCT 
P993R CCT  CGT 
For: CCA AGT TTG GGG GCC GTA ACA 
CCA AGA AGC A 
Rev: TGC TTC TTG GTG TTA CGG CCC 
CCA AAC TTG G 
T995I ACC  ATC 
For: TTG GGG GCC CTA ACA TCA AGA 
AGC AGT GCT G 
Rev: CAG CAC TGC TTC TTG ATG TTA 
GGG CCC CCA A 
V1001K GTA  AAA 
For: CAC CAA GAA GCA GTG CTG TAA 
ATA CCG GAA GTG TGA CAA A 
Rev: TTT GTC ACA CTT CCG GTA TTT 
ACA GCA CTG CTT CTT GGT G 
VY1001-2KM GTA+TAC  AAA+ATG 
For: GCC CTA ACA CCA AGA AGC AGT 
GCT GTA AAA TGC GGA AGT GTG 
ACA AAA TAG AGG 
Rev: CCT CTA TTT TGT CAC ACT TCC 
GCA TTT TAC AGC ACT GCT TCT 
TGG TGT TAG GGC 
R1011M CGG  ATG 
For: GTG TGA CAA AAT AGA GGC TAT 
GAA GAT GGA AGG ATC CCC C 
Rev: CAC ACT GTT TTA TCT CCG ATA 
CTT CTA CCT TCC TAG GGG G 
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mutagenesis reactions (T995I and R1011M), the PCR reaction was set up with 
temperature decrements (“touchdown mode”) in which the annealing temperature was 
begun at 62°C (higher than the recommended 55°C) for four cycles to facilitate the 
specific annealing of the mutant primers, with the annealing temperature then decreased 
4°C every four cycles until the annealing temperature of 50°C was reached for the final 
six cycles (18 total cycles): 4 cycles at 62°C, 4 cycles at 58°C, 4 cycles at 54°C, and 6 
cycles at 50°C.  Following the 1 hour digestion of all reactions with Dpn1 at 37°C to 
remove the residual wild type template from the reaction mixture, 50µL of XL1-Blue 
supercompetent cells (provided in kit) were transformed with 1µL of the mutagenesis 
PCR product and plated on LB agar with kanamycin (25µg/mL) selection.  Individual 
colonies from each mutagenesis reaction were grown, plasmid DNA purified from each 
clone, and constructs sequenced using the M13R primer to verify that the correct 
mutation was present with no other alterations in the DNA sequence. 
The sequence-verified clones were then subjected to double digestion (like the 
wild type pCR-Blunt-MLL2 CXXC construct above) using AatII and BamHI (NEB or 
Fermentas FastDigest®) restriction enzymes in 40µL reaction volumes and ~5ng of 
mutant MLL2 CXXC plasmid DNA per reaction.  The digested, mutant MLL2 CXXC 
constructs were gel purified and swapped into the pMCS5-5’MLL/MLL2(wt. CXXC + 
‘post-CXXC’) construct (Table 2, F) using the AatII and BamHI restriction sites as was 
done to exchange the wild type MLL2 CXXC sequence above.  The mutant constructs 
were subsequently subcloned into the larger fusion construct like the wild type version 
using the same restriction enzyme sites and three-way ligation technique described above.  
The constructs were sequenced at each step to verify the accuracy of the inserts including 
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the presence of the desired mutation(s) and the maintenance of the necessary reading 
frame through all restriction site junctures that make up the final pMSCVneo-
MLL/MLL2(mt CXXC + ‘post-CXXC’)-AF9 constructs (Table 2, I). 
Production of Retrovirus 
Plasmid DNA of the pMSCVneo (negative control), pMSCVneo-MLL-AF9 
(positive control), and pMSCV-MLL/MLL2(wt./mt. CXXC ± ‘post-CXXC’)-AF9 
constructs was purified from 250mL overnight bacterial cultures in LB selection media 
using the Plasmid Purification Midi Kit (Qiagen, #12145).  Centrifugation steps were 
performed using a high-capacity, floor model centrifuge (Beckman, #J2-MI) and the 
corresponding JA-10 and JA-20 rotors.  The final DNA pellet was dissolved in 10mM 
Tris, pH 8.0 and the concentration determined using a NanoDrop 2000. 
Five plates of PhoenixTM Ecotropic virus-packaging cells (Allele Biotech. & 
Pharm. Inc., #ABP-RVC-10002) were plated at 3x106 cells per 10cm2 dish for each 
construct on Day 1.  These cells were allowed to grow overnight in HyClone® 
Dulbecco’s Modified Eagle’s Medium, DMEM/High Glucose (Thermo Scientific, 
#SH30022.01), with 1% penicillin/streptomycin and 10% fetal bovine serum 
(DMEM/1%P/S/10%FBS) at 37°C in a Heraeus incubator to achieve 50-60% confluence 
by the time of transfection on Day 2.  Each plate of cells was transfected with 25µg 
plasmid DNA using the calcium phosphate CalPhosTM Mammalian Transfection Kit 
(ClonTech, #631312).  Cells were incubated overnight at 37°C in 5% CO2 with culture 
media containing the DNA plasmid and calcium phosphate complexes.  This calcium 
phosphate-containing media was removed after ~16 hours on Day 3 and replaced with 
fresh media lacking calcium phosphate.  The cultures were transferred to 32°C and 5% 
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CO2 and the virus-containing media was collected from and replaced for each plate at 24-
hour intervals for two days (Days 4 and 5).  The media from plates containing identical 
constructs was pooled together on Day 5.  The retroviral packaging cells were harvested 
in 1x sterile phosphate buffered saline (PBS) for detection of stable fusion protein 
production via Western Blot at a later date.  The cells were pelleted in aliquots of 107 
cells in a Beckman GS-6KR centrifuge at 1500 rpm and 10°C and snap frozen on dry ice 
for storage at -80°C. 
The pooled media containing the virus particles of each construct type was added 
to a primed Centricon® Plus-70 filter (Millipore, #UFC10008) for concentrating the virus 
supernatant.  The viral media was filtered via centrifugation at 1640rpm and 25°C in a 
Beckman GS-6KR centrifuge for 1.5-2 hours until all but 1-2mL had entered the filter.  
The filters were inverted onto a collection reservoir and centrifuged in a benchtop 
centrifuge (Sorvall, #RT6000B) for 10 minutes at 3000rpm and 25°C to release the 
concentrated media containing the virus particles.  The volume of the virus supernatant 
was adjusted to a final 7x virus concentration by adding the appropriate volume of 
HyClone® Roswell Park Memorial Institute (RPMI)-1640 media (Thermo Scientific, 
#SH30027.01) with 1% P/S and 20% FBS.  The concentrated supernatants were 
separated into aliquots of 750µL, snap frozen on dry ice, and stored at -80°C. 
Determination of Retrovirus Titer 
The concentration of retrovirus was determined by infecting Rat1a fibroblast cells 
with serially diluted virus supernatant and was measured by the ability of the cells to 
form colonies in the presence of antibiotic selection.  In this manner, colony formation 
would indicate effective viral uptake and expression of the desired plasmid through 
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acquired resistance to the antibiotic.  A high number of colony forming units (CFUs) 
corresponds with a high virus titer, especially when the high number of colonies is 
formed in a well where the virus had been present in a low dilution.  To measure the virus 
titer, a standardized number of 85,000 Rat1a cells was plated in each well of a 6-well 
plate (i.e. 1 6-well plate per retroviral construct), and the cells were allowed to grow 
overnight at 37°C and 5% CO2 in DMEM/1%P/S/10%FBS.    A series of 10-fold virus 
dilutions were made ranging from 10-2 to 10-6 in 1-mL volumes of DMEM/10%FBS with 
16µg/mL polybrene (without the 1% P/S that was previously used).  Polybrene, a 
positively charged polymer, was added to the media to increase viral uptake efficiency by 
helping to neutralize repulsive negative charges on the cell surfaces.  The day-old culture 
media from each well was replaced with this 1-mL of fresh media containing a diluted 
virus: 10-2, 10-3, 10-4, 10-5, 10-6, or 1mL of polybrene-containing media with no virus.  
The cultures were returned to 37°C for 4 hours to allow the cells to take up the virus after 
which time 1ml of fresh DMEM/10%FBS without polybrene or P/S was added to each 
well.  The cultures were allowed to grow overnight at 37°C and 5% CO2.  The following 
morning, the media was replaced with 2mL of fresh DMEM/10%FBS, and 1 mg/mL of 
HyClone® G418 antibiotic (Thermo Scientific, #SV30069.1) was added to each well to 
select for Rat1a cells which took up the retrovirus and express the neomycin resistance 
gene from the pMSCV constructs.  Cultures were incubated at 37°C and 5% CO2 for 
twelve days while changing the media as needed (usually every fourth day) and 
maintaining the G418 antibiotic selection for the duration of the culture period.  At the 
end of the twelve days of selection, the media was removed from each well, and 
methylene blue dye (1.7µg/mL in methanol) was added to each well to stain Rat1a 
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colonies.  The number of colonies in each well was counted as a colony forming unit 
(CFU), and the virus titer for each construct was determined by the average number 
colonies in each well of serially diluted virus. 
Isolation of murine bone marrow cells 
Six- to twelve-week old C57Bl/6, male mice (Taconic, #C57BL/6NTac) were 
euthanized via CO2 inhalation.  The femurs and tibias were collected and cleaned using 
sterile surgical technique and placed in RPMI/2%FBS.  The marrow cavities of the bones 
were flushed into a culture dish with this RPMI/2%FBS using a 1mL, 25-gauge, 
EclipseTM Injection Needle with Luer-LokTM Syringe (BD, #305780).  The cells were 
pelleted by centrifugation (Beckman GS-6KR) at 1500rpm and 4°C for 5 minutes and 
resuspended in sterile, chilled 1x red cell lysis buffer (10x red cell lysis buffer: 1.55M 
NH4Cl, 120mM NaHCO3, 1.3mM EDTA).  Resuspended cells were incubated at room 
temperature with periodic mixing for about 5 minutes until the red tint was no longer 
visible.  This mixture was then passed through a nylon 70µm cell strainer (BD Falcon, 
#352350) to remove any debris.  The remaining cells (the viable white blood cells from 
the bone marrow) were pelleted, resuspended in sterile 1x PBS, and counted using a 
hemocytometer counting chamber (Hausser Scientific, #3200) and 0.4% trypan blue stain 
(Gibco, #15250-061).  The mice were handled and housed in compliance with LUMC 
Comparative Medicine Facility and I.A.C.U.C. policies. 
CD117 positive selection of murine bone marrow progenitor cells 
The isolated white blood cells from the mouse bone marrow underwent selection 
for the c-kit (CD117) cell surface marker using the EasySep® Mouse CD117 Positive 
Selection Kit (Stem Cell Technologies, #18757).  Specifically, isolated white blood cells 
47 
were resuspended in sterile PBS/2%FBS to a final concentration of 1x108 cells/mL in a 
round-bottom Fisherbrand® 12x75mm polypropylene culture tube (Fisher, #14-956-10).  
The CD117 PE Labeling Reagent (containing c-kit antibody) was added to the cells at 
50µL per 1-mL volume of cells, mixed, and allowed to incubate for 15 minutes at room 
temperature.  Next, the EasySep® PE Selection cocktail containing a bispecific 
tetrameric antibody complex (recognizing both c-kit/CD117 and dextran) was added at 
70µL per 1-mL volume of cells, mixed, and incubated at room temperature for 15 
minutes.  Resuspended Magnetic Nanoparticles coated with dextran were then added at 
50µL per 1-mL volume of cells, mixed, and incubated at room temperature for 10 
minutes.  The suspension volume was brought up to 2.5mL by adding PBS/2%FBS and 
the tube was set inside the EasySep® Magnet (Stem Cell Technologies, #18000) without 
the tube cap and was incubated for 5 minutes at room temperate to magnetically separate 
the c-kit positive bone marrow progenitor cells.  Next, while the tube remained inside the 
magnet, the supernatant was smoothly decanted in a single motion leaving the 
magnetically-separated c-kit positive cells within the tube.  The tube was removed from 
the magnet, and the cells were washed with 2.5mL PBS/2%FBS and, again, incubated 
within the magnet without the tube cap for 5 minutes.  This wash and incubation step was 
repeated for a total of four separations.  The washed cells, having been positively selected 
based on c-kit/CD117 cell-surface expression, were counted and resuspended in 
RPMI/10%FBS/1%P/S which was supplemented with 0.05 mM β-mercaptoethanol, 
50ng/mL SCF, 10ng/mL IL-3, and 10ng/mL IL-6 at a final concentration of 106 cells/mL.  
The cells were incubated in a humidified round-bottom, 96-well plate overnight at 37°C 
and 5% CO2. 
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Retroviral transduction of c-kit positive bone marrow progenitor cells 
The spinoculation method for was used for transducing c-kit positive bone 
marrow progenitor cells. 30,000 cells which had been selected on the previous day were 
added to a mixture of 750µL of concentrated viral supernatant, 7.5mM HyClone® 
HEPES solution (Thermo Scientific, #SH30237.01), 4µg/mL polybrene (also called 
hexadimethrine bromide from Sigma, #H9268), and RPMI/10%FBS to a final volume of 
5mL in a conical 12x75mm culture tube (VWR, #60818-102).  (Two aliquots—1.5mL 
total—of virus supernatant were used for the V975P and V982T constructs since these 
retroviruses had lower yields in the 104 CFU range.  The total spinoculation volume was 
10mL for these constructs, and the volumes of the other components were doubled 
accordingly to maintain the concentrations.  Spinoculation with the empty vector, 
pMSCVneo retrovirus was conducted using half a volume of supernatant, 375µL, in a 
total volume of 1mL.)  The spinoculation mixture was briefly mixed by vortexing and 
then subjected to centrifugation (Beckman GS-6KR) at 3000rpm and 33°C for 4 hours.  
Following spinoculation, the supernatant was removed, and the cells were resuspended in 
200µL of fresh RPMI/10%FBS/1%P/S supplemented with 0.05mM β-mercaptoethanol, 
50ng/mL SCF, 10ng/mL IL-3, and 10ng/mL IL-6.  The cells were incubated in a 
humidified round-bottom, 96-well plate overnight at 37°C and 5% CO2.  The following 
day, the cells underwent a second spinoculation using the same volumes and components 
as the previous day.  After this second spinoculation, the retrovirally transduced cells 
were plated in methylcellulose as described below. 
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Methylcellulose Colony Assay 
Transduced c-kit positive hematopoietic progenitor cells were plated at 1,000-
10,000 cells per 35mm culture plate depending on the observed transformation capacities 
of the various retroviral fusion constructs.  Cells were added to MethoCult® M3234 
Methylcellulose Medium for Mouse Cells (Stem Cell Technologies, #03234) which had 
been supplemented with glutamine, 50ng/mL SCF, 10ng/mL IL-3, 10ng/mL IL-6, and 
10ng/mL GM-CSF.  For the first round of plating immediately following viral 
transduction, 1.25mg/mL of HyClone® G418 antibiotic (Thermo Scientific, 
#SV30069.1) was added to the semi-solid media to select for those progenitor cells which 
were effectively transduced with the retrovirus and stably expressing the plasmid of 
interest.  This mixture of cells, methylcellulose, cytokines, and antibiotic were thoroughly 
vortexed to generate a homogeneous culture.  A 16-gauge, 1.5” blunt-end needle (Popper, 
#SBN16X1-1/2) was added to a 3ml syringe with Luer-LokTM Tip (BD, #309657) and 
both were primed by flushing with culture medium to remove all residual air.  1.1mL of 
culture medium containing the cell/methylcellulose/cytokine mixture ± antibiotic was 
added to each of two tissue culture-treated 35-mm dishes (CytoOne, #CC7682-3340).  
The plates were gently rocked to evenly distribute the culture media throughout the plate.  
The smaller 35-mm dishes were added to a larger humidified chamber and incubated at 
37°C for six days to allow for colony formation. 
At the end of 6-days, the number of colonies on each plate was counted, reported 
as colony forming units (CFUs), and all CFUs were normalized to an initial number of 
10,000 cells plated per dish.  Each construct had two plates of cells grown in parallel, and 
the number of CFUs was averaged between these two plates for the final, normalized 
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CFU count of each round.  Pictures of representative colony morphology were taken on a 
Leica DMIL microscope at 4x objective magnification with a Canon PowerShot S40 
digital camera and acquired with Canon Utilities ZoomBrowser EX v3.2 software. 
Cells from each round of plating were harvested by diluting the semi-solid 
methylcellulose media in sterile PBS and transferring to a conical tube for centrifugation.  
The number of viable cells was counted on a hemocytometer by trypan blue staining and 
reported as a total cell number normalized to 10,000 cells initially plated.  1,000-10,000 
cells transduced with each construct were re-plated in methylcellulose media without 
G418 antibiotic for subsequent rounds (at least 3) to determine replating and proliferative 
potential of each fusion construct.  Remaining cells from each round were frozen for 
viability in bone marrow freezing media (RPMI/47.5%FBS/7.5%DMSO) at a rate of -
1°C/minute in an isopropanol Cryo 1°C Freezing container (Nalgene, #5100). 
Colony assays for hydrogen peroxide (Sigma, #U8879-50TAB), parthenolide 
(Sigma, #P0667), and spermine nonoate (Sigma, #S150) toxicity assays were performed 
in the same manner as described above using MLL-AF9 and MLL(C1188A)-AF9 cells 
that had been previously transformed11.  These cells were treated overnight with varying 
concentrations of compound prior to being plated in methylcellulose at 1,000-2,000 cells 
per plate and incubated for 5-7 days. 
For the colony assays with varying oxygen concentrations, untreated MLL-AF9 
and MLL(C1188A)-AF9 cells were plated in methylcellulose with the appropriate 
cytokines in equal numbers and placed inside an airtight, humidified, modular incubator 
chamber (Billups-Rothenberg, #MIC-101).  (Cultures grown under 21% O2 were not 
placed in an airtight chamber and were instead simply placed in an incubator containing 
51 
room air: 21% O2/5% CO2/74% N2) The chamber was then flushed with air containing 
various oxygen concentrations (1, 5, or 60% O2 with 5% CO2 and balanced by N2 from 
MedOx, #G1803961, G1811061, and G1806151, respectively) using a Harris two-stage 
regulator, and the gases were allowed to equilibrate for 1-2 hours before the chambers 
were flushed with the same gas for a second time to ensure a stable oxygen concentration.  
Air chambers were placed in a 37°C incubator for 5-6 days to allow for cell growth and 
colony formation.  Following this incubation period, colony numbers were analyzed and 
compared. 
Cytospin for cell morphology 
Approximately 50,000 cells were suspended in less than 400µL and fixed to 
coated Shandon Cytoslides® (Thermo Scientific, #5991056) using Single Cytology 
Funnels (Fisher Scientific, #10-354) and centrifuged in a Cytospin 4 (Thermo Scientific) 
at 1000rpm for 4 minutes with medium acceleration.  Cytopsun slides were allowed to air 
dry overnight at room temperature.  Cells were stained with HEMA-FAST 3 Step Stain 
(Exaxol Chemical Corp., #SH6427G, #SH6427R, #SH6427B).  Cover slips were affixed 
to the slides with Richard-Allen Scientific CytosealTM 60 (Thermo Scientific, #8310-4) to 
preserve the integrity of the samples.  Photos of cell morphology were obtained on an 
Olympus Provis AX80 microscope at 40x objective magnification using a multi control 
unit (Olympus, #U-MCB) and a Q-Imaging Retiga-4000R digital camera (Model RET-
4000R-F-M-12-C).  Images were acquired using the QCapture Plug-In and Adobe 
Photoshop v6.0 software.  Scale bars were determined using a stage micrometer 
(Graticules LTD) with millimeter gradations (LUMC Core Imaging Facility). 
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RNA Isolation 
RNA from frozen, Round 1, colony assay cells (8.5x104 to 5.82x106 cells) was 
isolated with TRI Reagent® (Sigma, #T9424).  Specifically, the frozen cells were quickly 
thawed at 37°C and washed with pre-warmed RPMI media to remove DMSO.  The 
washed cells were lysed in 500µL TRI Reagent® for 5 minutes at room temperature.  
100µL of chloroform was added to the mixture was shaken, and incubated at room 
temperature for 10 minutes after which point the solution was centrifuged at 12,000xg 
and 4°C for 15 minutes to separate mixture into three distinct layers.  The upper, clear 
aqueous layer containing the RNA was transferred to a new tube, being careful not to 
transfer the precipitated DNA from the adjacent, middle layer.  250µL isopropanol was 
added to the isolated aqueous layer and incubated at room temperature for 10 minutes.  
The solution was centrifuged at 12,000xg and 4°C for 10 minutes.  The supernatant was 
discarded leaving behind the precipitated RNA pellet which was washed with 1mL 75% 
molecular-grade ethanol (Absolute 200 Proof, AAPER Alcohol, #02A02UA) and 
resuspended by vortexing.  After centrifugation at 7,500xg and 4°C for 5 minutes, the 
supernatant was removed, and the pellet was air dried for ~10 minutes.  The RNA pellet 
was dissolved in RNase-free dH2O (DEPC-treated dH2O, de-gassed, and autoclaved).  
The concentration of the total isolated RNA was measured using the NanoDrop 2000. 
Generation of cDNA 
The isolated RNA from Round 1 colony assay cells was reverse transcribed into 
cDNA using a High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, 
#4368814).  10µL of RNA from each construct (not exceeding 2µg of RNA) was added 
to reaction mixtures containing 10x RT Buffer, 25x dNTP Mix, and 10x RT Random 
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Primers with or without (control to detect DNA contamination) MultiScribeTM Reverse 
Transcriptase according to the supplier’s protocol.  The cDNA was generated via RT-
PCR in a PCR Express Thermal Cycler using the cycling parameters described in the kit. 
Quantitative RT-PCR 
Quantitative Reverse-Transcriptase PCR—or Real Time PCR—was used to 
determine gene expression levels of Hoxa9 bone marrow progenitor cells from Round 1 
of the methylcellulose colony assay.  The qRT-PCR reaction mixture was prepared using 
the TaqMan® Gene Expression Assay kit (Applied Biosystems).  Each 20µL qRT-PCR 
reaction mixture was performed in triplicate with 4µL RT-PCR product (either cDNA or 
the no RT control products), 10µL 2x Gene Expression Master Mix (AB, #4324018), and 
1µL of either 20x Gene Expression Assay for Hprt1 (endogenous control, 
Mm01545399_m1) or Hoxa9 (Mm00439364_m1).  Triplicate samples (including, non-
template controls) were distributed among the wells of a 0.2mL Thin Wall, Non-Skirted, 
96-well PCR plate (Dot Scientific Inc., #650-PCR) and sealed with ThermalSeal RTTM 
Optically Transparent Sealing Film (Dot Scientific Inc., #TSRT2100).  The qRT-PCR 
reaction was run on an Applied Biosystems 7300 Real-Time PCR System using the 
following cycling parameters: 50°C for 2 minutes, 95°C for 10 minutes, and then 40 
cycles alternating between 95°C for 15 seconds and 60°C for 1min.  The data was 
acquired with 7300 System software (Applied Biosystems) and analyzed using the 2-ΔΔCt 
method159.  The relative Hoxa9 expression levels were normalized to endogenous Hprt1 
expression levels. 
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Generation of GST fusion repression domain constructs 
The nucleotide sequences encoding the MLL and MLL1/2 repression domains 
(RD) were PCR amplified from pMSCV-MLL-AF9 and pMSCV-MLL/MLL2(wt. 
CXXC + ‘post-CXXC’)-AF9 constructs, respectively, using the cloning primer sequences 
listed Table 3.  The forward primer contains a NruI restriction site which forms a blunt 
end when digested with NruI and could subsequently be ligated to the EcoRV blunt end 
of the GST expression vector, pGS-21a (GenScript, #SD0121-10ug).  The reverse 
primers for cloning the RD constructs contain the SalI site that was used previously.  The 
RD sequences were PCR-amplified using a Phusion® high-fidelity DNA polymerase 
(Finnzymes/NEB, #F530S), were ligated into the pCR-Blunt holding vector, and 
transformed into OneShot® Top10 chemically competent E.coli using the Zero Blunt® 
PCR Cloning kit described previously.  The accuracy of the amplified RDs was verified 
by sequencing with the M13R primer. 
Then, the purified pCR-Blunt-MLL-RD or –MLL1/2 -RD constructs were 
digested simultaneously with NruI (NEB) and SalI (NEB) in a 50µL reaction volume 
containing NEB Buffer #3 for 1.5 hours at 37°C.  The digested RD fragments were 
separated by electrophoresis on a 1% agarose gel (20 minutes at 90V) and gel purified.  
The empty GST expression vector, pGS-21a, was digested with EcoRV (Amersham) and 
SalI (NEB) in a 50µL reaction volume containing NEB Buffer #3 for 2 hours at 37°C.  
This digest reaction was heat-inactivated at 65°C for 15 minutes and 2µL of CIP (NEB) 
was added to prevent self-ligation of the linearized vector which was subsequently 
purified through gel extraction.  The digested RD constructs were ligated with the 
linearized pGS-21a GST expression vector in a 10µL reaction with T4 DNA ligase 
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(Fermentas) for 1 hour at 16°C to generate the wild type repression domain constructs of 
pGS21a-MLL-RD and pGS21a-MLL1/2-RD (Table 2, J).  The inserts encoding the RDs 
were sequence-verified using the universal T7 terminator primer. 
The sequences encoding the mutant MLL2 CXXC domains (A964R, R970P, 
LRVQ973-6QVPE, V1001K, and R1011M) were swapped into the pGS21a-MLL1/2 
repression domain construct in exchange for the wild type nucleotide sequence of MLL2 
CXXC domain using the same unique AatII and BamHI restriction sites as were 
previously used to swap these domains during the cloning of the AF9 fusion constructs.  
The sequences of each mutant repression domain were verified using the T7 terminator 
primer. 
Bacterial over-expression of GST fusion MLL- and MLL1/2 repression 
domain constructs 
 
The pGS21a repression domain constructs were transformed into chemically 
competent BL21(DE)pLysS cells (Novagen, #69451-3) to maximize expression of the 
GST fusion constructs.  Briefly, 1µL of plasmid DNA was added to 20µL of thawed 
BL21(DE)pLysS cells in a 15-mL round bottom culture tube on ice and incubated for 5 
minutes.  Cells were heat shocked at 42°C for 30 seconds and transferred back to ice for 2 
minutes before adding 80µL of room temperature S.O.C. medium and shaking at 37°C 
and 225rpm for 1 hour.  Transformed cells were plated on LB agar plates for ampicillin 
selection and grown overnight to allow bacterial colonies to form. 
A freshly plated colony of BL21(DE)pLysS cells expressing each pGS21a-MLL 
or –MLL1/2(wt./mt CXXC + ‘post-CXXC’) repression domain construct was picked and 
used to inoculate 100mL of LB broth with ampicillin (100µg/mL) and chloramphenicol 
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(15µg/mL, Sigma, #C0378) overnight in a shaker at 225rpm and 37°C.  The following 
morning, the 100-mL cultures were diluted 1:10 by adding 900mL LB Broth with 
ampicillin but no chloramphenicol.  The cultures were grown for about 3 hours until an 
O.D.600 of at least 0.5 was reached (Beckman DU® 530 Life Science UV/Vis 
Spectrophotometer). Protein production was then induced by adding 1mM IPTG 
(Research Products Int. Corp., #367-93-1) for 3 hours with continued shaking of the 
cultures at 225rpm and 37°C.  Cultures were then pelleted at 6000xg in a JA-10 rotor of 
the high capacity Beckman J2-MI centrifuge, and the pellets were frozen at -20°C. 
Purification of GST fusion repression domain constructs 
Frozen bacterial pellets were thawed on ice and resuspended in 60mL Lysis 
Buffer (50mM Tris, pH 8.0, 300mM NaCl, 1mM EDTA) with protease inhibitor cocktail 
(1 Roche tablet, #04 693 132 001, per 50mL buffer) and PMSF (1:1000).  Lysozyme 
(1mg/mL) was added directly from powder to the resuspension mix followed by Triton 
X-100 to a final 1% concentration.  The lysis mixture was inverted frequently while 
incubating on ice for 5 minutes.  The lysate was then sonicated two times for 20 seconds 
while on ice with the Output Control set to 5 (Branson Sonifier 250).  The lysate was 
transferred to centrifugation tubes and spun at 9000rpm and 4°C for 30 minutes in the 
JA-20 rotor of the Beckman J2-MI centrifuge.  The supernatant was transferred to a fresh 
tube and 500µL of a 50% slurry of swollen and washed Glutathione-agarose beads 
(Sigma, #CL-4B) was added to the supernatant.  The solution was incubated end-over-
end at low to medium speed on a Rugged Rotor (Glas-Col®) at 4°C for 2 hours to allow 
the Glutathione-agarose beads to bind the GST fusion constructs.  The beads were then 
pelleted and washed four times with cold Wash Buffer (lysis buffer including the 1% 
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Triton X-100, protease inhibitors, and PMSF).  Washed beads were resuspended in a 
volume of this wash buffer to create a 50% slurry of beads.  All steps were performed on 
ice or at 4°C. 
Purified GST proteins were detected by SDS-PAGE (4% stacking and 10% 
resolving acrylamide gel) using the BioRad Mini-PROTEAN® 3-Cell System followed 
by Coomasie staining or by Western Blot with a rabbit polyclonal anti-GST primary 
antibody (Abcam, #ab19256) and an ECLTM donkey anti-rabbit secondary antibody 
conjugated to Horseradish Peroxidase (GE Healthcare, #NA934V).  The blot was 
developed with SuperSignal® West Pico Chemiluminescent Substrate (Thermo 
Scientific, #34078) and exposed to CL-XPosureTM Film (Thermo Scientific, #34090), or 
the chemiluminescence was detected using a Fujifilm LAS-3000 imaging system and 
Image Reader LAS-3000 software.  Band intensities were analyzed with Multi Gauge 
v3.0 software (Fujifilm). 
In vitro transcription and translation 
HDAC1 (pcDNA3-HDAC1-FLAG Glycerol Stock #562/563), HPC2 (pcDNA3-
T7-HPC2, Glycerol Stock #658), and PAF1 (pcDNA3-PAF1, Addgene #11059, Glycerol 
Stock #1136) proteins were expressed using the TNT® T7 Coupled Reticulocyte Lysate 
System (Promega, #L4610).  Plasmid DNA was purified using the Midi Kit from Qiagen 
to be used as the template for the IVTT reaction.  The reaction components were 
combined according to the supplier’s protocol using 1.0µg template DNA, the amino acid 
mixture minus methionine, RNase Inhibitor (Applied Biosystems, #AM2682), and L-
[35S]-Methionine, aqueous solution (PerkinElmer, #NEG709A500UC) to radioactively 
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label the IVTT proteins for detection via phosphorimaging.  The reaction was incubated 
at 30°C for 90 minutes. 
5µL of each IVTT reaction mixture was electrophoresed on an SDS-
polyacrylamide gel (4% stacking, 10% resolving) to compare the reaction efficiencies 
before the IVTT proteins would be used for protein binding studies.  The electrophoresed 
gel was dried on filter paper (BioRad gel dryer, #583).  The radioactive gel was exposed 
to a blanked Imaging PlateTM (Fujifilm, #BAS-IIIs) for 4 to 12 hours within a Standard 
BAS Cassette (Fujifilm, #2040).  The signal from the Imaging PlateTM was, then, 
detected with a Typhoon 8600 Variable Mode Imager and Typhoon Scanner Control v1.0 
software (Molecular Dynamic Inc., Amersham) using the Storage Phosphor acquisition 
mode with a pixel size of 50 microns.  ImageQunat TL v2005 software (Amersham) was 
used to analyze signal intensities generated by the 35S-labeled proteins. 
In vitro protein binding assay 
Equivalent amounts of purified GST repression domain proteins were combined 
with 20 to 30µL of HDAC1, HPC2, or PAF1 IVTT reaction product depending on the 
expression efficiency of the 35S-labeled protein.  The binding volume was brought up to 
100µL for all reactions by adding Wash Buffer (described above).  GST-tagged 
repression domain proteins and IVTT proteins were incubated together on an end-over-
end rotor at low to medium speed at 4°C for 2 hours.  Beads were then washed 4 times 
while on ice with chilled Wash Buffer (1mL per wash).  Interacting proteins were eluted 
from the beads by adding SDS loading buffer to the washed beads and boiling at 95°C for 
5-10 minutes.  The eluted proteins were separated by SDS-PAGE and bands were 
detected as described above.  Detected bands of interacting 35S-labeled IVTT proteins 
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(HDAC1, HPC2, or PAF1) were quantified relative to the GST-MLL-RD binding 
intensity and normalized to the amount of each GST input. 
FLAG-tagged CtBP was overexpressed in 293T cells by transient transfection 
using the calcium phosphate kit described previously.  48 hours after transfection, cells 
were collected, pelleted, and snap frozen on dry ice in aliquots of 107 transfected cells, 
and stored at -80°C.   When needed, cell aliquots were thawed on ice and resuspended in 
500µL IPH Buffer (50mM Tris, pH 8.0, 150mM NaCl, 5mM EDTA, 0.5% NP-40, and 
protease inhibitor cocktail 1:200).  The cell lysates were incubated on ice for 10 minutes 
and then centrifuged at >14,000rpm and 4°C for 30 minutes.  The supernatant was snap 
frozen on dry ice and stored at -80°C until used in the in vitro binding study.  Prior to the 
binding experiments, equal amounts of each GST-tagged repression domain protein were 
incubated on ice for 15 minutes with 200µL of Z’Buffer (25mM HEPES, pH 7.5, 
12.5mM MgCl2, 150mM KCl, 0.1% NP-40, 20mM Tris pH 8.0), BSA (1mg/mL), PI 
cocktail and PMSF (1:1000). 25µL of CtBP-FLAG-containing cell lysate was added to 
each GST-repression domain protein and incubated end-over-end at low to medium speed 
at 4°C for 2 hours.  Glutathione beads were washed four times with 1mL chilled NETN 
buffer (100mM NaCl, 1mM EDTA, 0.5% NP-40, 20mM Tris pH 8.0).  Bound proteins 
were eluted from the washed beads by the addition of SDS loading buffer and boiling for 
5-10 minutes at 95°C.  Proteins were separated by SDS-PAGE and detected by Western 
Blot using a primary monoclonal mouse anti-FLAG M2 antibody (Sigma, #F3165) and a 
secondary ECLTM sheep anti-mouse secondary antibody conjugated to Horseradish 
Peroxidase (Amersham, #NA931V).  Band intensities of CtBP were calculated relative to 
the GST-MLL RD interaction and normalized to the amount of GST inputs. 
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MTT Assay 
The MTT assay was used as a measure of cell proliferation and viability.  The 
MLL-AF9 and MLL(C1188A)-AF9 transformed cell lines had previously been generated 
in our lab by Laurie Risner, PhD, and were cultured in RPMI/20%FBS/1%P/S with 
50ng/mL SCF, 10ng/mL IL-3, 10ng/mL IL-6, and 10ng/mL GM-CSF 11.  The optimal 
cell numbers for the MTT assay were determined by serially diluting the cells (0 to 
400,000 cells) in 100µL of media per well of a 96-well flat-bottom plate in triplicate.  
MTT reagent, thiazolyl blue tetrazolium bromide (Sigma, #M5655), was added to cells at 
a final concentration of 0.5 mg/mL and incubated at 37°C for 6 hours after which purple 
formazan crystals were visible in the cultures.  Crystals were dissolved with the addition 
of 100µL of solubilization solution (10% Triton X-100, 0.1mM HCl, isopropanol to 
volume).  Absorbance of the reaction mix was measured at a wavelength of 550nm on a 
fluorescent plate reader and analyzed with Omega software.  For toxicity assays, 30,000 
MLL-AF9 or MLL(C1188A)-AF9 cells were pre-treated with varying doses of hydrogen 
peroxide (Sigma, #U8879-50TAB), parthenolide (Sigma, #P0667), or spermine nonoate 
(Sigma, #S150) and incubated overnight in a 96-well plate at 37°C and 5% CO2.  The 
following morning, MTT reagent was added as above.  All MTT reactions were set up 
using a multi-channel pipet and measured in triplicate. 
Statistical Analysis 
The data presented represent the averages of multiple experiments with error bars 
representing one standard deviation unless otherwise noted.  Statistical significance, 
where calculated, was determined by the two-tailed Student’s T-test for independent 
variables with the threshold for significance set at p < 0.05. 
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CHAPTER 4 
RESULTS 
Aim 1: Determine how differences in the MLL CXXC domain and the MLL2 
CXXC domain contribute to different transformation capacities of MLL/MLL2-
AF9 fusion proteins 
 
Comparison of co-repressor and co-activator protein interactions with MLL and 
MLL1/2 repression domains 
 
 The MLL repression domain (amino acids 1100-1400) has previously been shown 
to interact with transcriptional co-repressor proteins (HDAC1, HPC2, and CtBP) and co-
activator, PAF1, but it is unknown if the closely related homolog, MLL2 (also known as 
MLL4), interacts with these proteins.  A Glutathione-S-transferase (GST) pull-down 
assay was conducted to determine if these cofactors also interact with residues of the 
MLL2 repression domain.  A GST-tagged construct was generated in which the ‘pre-
CXXC’ residues of MLL (amino acids 1100-1151) were fused to the CXXC and ‘post-
CXXC’ residues of MLL2 (amino acids 958-1172) which align with the MLL repression 
domain (Figure 6A).  This MLL 1/2 repression domain construct was expressed in 
bacteria and purified with immobilized glutathione-agarose.  Equal amounts of 
immobilized GST protein were incubated with cofactor proteins which were expressed by 
in vitro transcription and translation, IVTT, (HDAC1, HPC2, or PAF1) or by transient 
transfection in 293T cells (CtBP).  Following incubation and washing, bound proteins 
were electrophoresed on a SDS-PAGE gel, and the interactions were detected by 
phosphorimaging (35S-labeled HDAC1 and HPC2) or Western blot (FLAG-tagged CtBP).
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Figure 7. HDAC1 binds to both the MLL repression domain and 
the equivalent MLL1/2 repression domain. 
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(A) GST fusion constructs generated for pulldown assays (not drawn to scale).  
GST—isolated GST domain (negative control); MLL—MLL repression domain 
(amino acids 1100-1400) fused to GST; MLL 1/2—chimeric repression domain 
consisting of MLL ‘pre-CXXC’ residues (MLL amino acids 1100-1151) and the 
MLL2 CXXC and ‘post-CXXC’ residues aligning with the MLL repression domain 
(MLL2 amino acids 958-1172); mt. MLL 1/2—chimeric MLL 1/2 repression domain 
with amino acid substitution(s) which restore MLL2 CXXC domain residue to 
corresponding MLL residue. 
(B) Phosphorimaging analysis of 4-5 independent GST pulldown assays showing 
relative 35S-labeled HDAC1 binding.  (Mean ± 1 S.D.)  A representative 
phosphorimage is shown below along with a Western Blot (bottom) of GST inputs.  
Detected bands of interacting HDAC1 were set relative to the intensity of the MLL 
band and normalized to the amount of each input GST protein. (p > 0.05 by Student’s 
T-test for all interactions compared to MLL1/2 binding, *except GST control.)
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Figure 8. HPC2 binds to both the MLL repression domain and the 
equivalent MLL1/2 repression domain. 
B
C
D
(A-C) Binding results for HPC2 and the various repression domain constructs from 3 
independent experiments. Results are relative to MLL binding and normalized to input 
GST protein. (D) Average HPC2 binding results from the three independent 
experiments  (Mean ± 1 S.D., p > 0.05 for all interactions).
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Figure 9. CtBP binds to both the MLL repression domain and the 
equivalent MLL1/2 repression domain.
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(Mean ± range).  A representative Western blot from one binding reaction is shown 
below along with a Western Blot (bottom) of GST input proteins.
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HDAC1, HPC2, and CtBP all bound specifically to the MLL 1/2 repression domain and 
the wild type MLL repression domain (positive control) with minimal or no binding to 
GST alone (negative control) (Figures 7-9).  HDAC1 and CtBP showed similar levels of 
binding to the repression domain constructs containing either the wild type MLL or the 
wild type MLL 2 CXXC domain (Figures 7 and 9).  In three independent experiments, 
however, HPC2 showed increased binding to the MLL 1/2 repression domain construct 
compared to the MLL repression domain (Figure 8).  When the HPC2 binding results 
were averaged from each experiment, though, the dynamic range of the binding 
intensities from individual experiments prevented this difference of HPC2 binding to the 
MLL and MLL1/2 RDs from achieving statistical significance (p > 0.05 by Student’s T-
test for all interactions). 
Determination of residues within the CXXC domain that alter co-repressor binding 
 I next wanted to determine if residues unique to MLL —when introduced into the 
MLL2 CXXC domain—would reduce or enhance binding of co-repressor proteins 
compared to binding of the wild type MLL2 CXXC domain.  To test the role of specific 
residues on protein binding, five constructs were generated in which amino acid 
substitutions were introduced into the MLL2 CXXC domain to convert this domain into 
the MLL amino acid sequence at each site: A964R, R970P, LRVQ973-6QVPE, V1001K, 
and R1011M (Figure 6A).  (These specific residues were chosen for these binding assays 
based on the results of in vitro transformation and Hoxa9 expression shown later in the 
results: Figure 16)  Interaction of the co-repressors with these mutant MLL2 CXXC 
domain constructs was performed out in the same manner as with the wild type constructs 
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above.  HDAC1, HPC2, and CtBP were still able to interact with each of the hybrid MLL 
1/2 constructs (Figures 7-9).  However, the substitution of some MLL amino acids into 
the MLL2 CXXC domain did alter the relative binding intensities of these proteins 
compared to the wild type MLL or MLL2 CXXC domain-containing constructs.  
Specifically, the R970P and R1011M substitutions both showed decreased binding of 
HDAC1 compared to the wild type MLL CXXC domain.  Additionally, the V1001K 
substitution reduced HPC2 binding from the wild type MLL1/2 domain levels toward the 
lower binding levels of the wild type MLL domain.  The differences in binding 
intensities, however, were not determined to be statistically significant (p < 0.05 by 
Student’s T-test). 
Comparison of co-activator PAF1 binding to residues of the MLL and MLL2 CXXC 
domains 
 
The PAF1 subunit of the polymerase associated factor complex was recently 
shown to interact directly with the N-terminus of MLL through the residues which flank 
the CXXC domain in a DNA-independent manner10.  Muntean et al showed that the 
interaction of PAF1 with an MLL fusion enhances transcription of leukemogenic target 
genes like Hoxa9 and Meis110.  Simultaneously, work by Milne et al showed that 
mutation of Arg1153 to alanine within the MLL CXXC significantly decreases binding of 
PAF1 to the first half of the MLL repression domain (amino acids 1101-1250) and also 
decreases expression of Hoxa99.  The authors also showed that the residues of MLL2 
which align with the first half of the MLL repression domain are unable to bind to PAF1.  
Taken together, these data suggest there are critical differences between MLL and MLL2  
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Figure 10. PAF1 binds to both the MLL repression domain and the 
equivalent MLL1/2 repression domain.
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within the CXXC domain and/or repression domain which affect the interaction of PAF1 
and recruitment of transcriptional activating complexes to MLL target genes. 
To better understand the role of specific residues within the MLL CXXC domain, PAF1 
binding with the MLL, MLL 1/2, and mutant MLL 1/2 repression domain constructs was 
compared in the same GST pull-down assay as described above.  35S-labeled PAF1 
directly interacted to the same degree with repression domain constructs containing both 
the MLL and the MLL2 CXXC domains.  Introduction of MLL residues (A964R, R970P, 
LRVQ973-6QVPE, V1001K, or R1011M) into the MLL2 CXXC domain did not 
enhance or diminish PAF1 binding suggesting that the residues of the MLL and MLL2 
CXXC domains do not show differential binding for PAF1 (Figure 10). 
Functional comparison of the capacity of MLL and MLL2 CXXC domain 
residues to transform bone marrow progenitor cells in vitro 
 
A previous study by Bach et al showed that introduction of both the MLL CXXC 
domain and ‘post-CXXC’ domain were necessary to confer a transforming capacity to an 
artificial MLL2-ENL fusion protein suggesting that there are critical residues within this 
region of MLL that are required for the oncogenic function of a MLL fusion protein7.  
Sequence alignment of the MLL and MLL2 CXXC domains shows conservation of the 
structural zinc-coordinating cysteines and the KFGG motif which are necessary for 
proper domain folding and recognition of non-methylated CpG DNA targets suggesting 
that other residue within the CXXC domain must account for the observed functional 
differences (Figure 12A)143, 160. 
In order to understand the critical role of specific amino acids within the CXXC 
domain, a chimeric fusion protein was generated in which the CXXC domain of MLL2 
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Figure 7. The MLL2 CXXC domain can transform primary bone 
marrow cells when swapped into a MLL-AF9 fusion protein.
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was exchanged for that of MLL in the context of the well-studied MLL-AF9 fusion 
protein.  This synthetic MLL/MLL2(CXXC)-AF9 fusion was able to transform primary 
hematopoietic cells in an in vitro colony assay in which a large number of tight colonies 
were formed in the third round of plating (Figure 11).  These colonies were comprised of 
blast-like cells similar to those of MLL-AF9 cells.  Quantitative RT-PCR showed 
increased levels of Hoxa9 compared to the negative control (MSCV-transduced) cells, 
although the expression levels were lower than that of MLL-AF9 cells (p < 0.01 by 
Student’s T-test).  The ability of the MLL2 CXXC domain to transform bone marrow 
progenitor cells suggests that MLL2 retains some important residues within the CXXC 
domain that are also present in MLL and are able to contribute to a transforming capacity 
of the chimeric protein. 
In order to be able to study the gain-of-function effects of individual CXXC 
domain residues, I needed to generate another fusion construct which had lower 
transforming potency.  A chimeric fusion protein was cloned in which the ‘post CXXC’ 
residues of MLL2 were swapped into MLL-AF9 along with the MLL2 CXXC domain to 
create a MLL/MLL2-AF9 fusion protein (Figure 12B).  In this context, I hypothesized 
that the wild type MLL/MLL2-AF9 construct—lacking the critical CXXC and ‘post-
CXXC’ domain residues from MLL—would be non- or minimally-transforming in vitro 
and would serve as a baseline control.  I further hypothesized that introduction of 
individual amino acid substitutions in this context (13 positions highlighted in blue in the 
sequence alignment of Figure 12) to restore the MLL sequence in the MLL2 CXXC 
domain could potentially rescue the MLL-fusion-transforming function (Figure 12B).  I 
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Figure 12.  Experimental design of in vitro colony assay.
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predicted that those MLL residues which have a critical role in the oncogenic capacity of 
an MLL fusion protein would rescue transformation capacity from the baseline levels of 
the wild type MLL/MLL2-AF9 cells in an in vitro methylcellulose colony assay. 
Determination of titers for retroviruses expressing the fusion proteins 
 To express the fusion proteins in bone marrow progenitor cells, retroviruses 
containing the respective fusion constructs in the MSCVneo vector were generated as 
described in the methods section above.  To determine the virus titer of each supernatant, 
Rat1a cells were infected with serial dilutions of supernatant.  After selection with G418, 
the number of surviving Rat1a colonies was counted as colony forming units (CFUs) to 
determine viral titers for each fusion construct (Figure 13).  The virus titers ranged from 
2.5x104 to 2.6x106 CFUs per milliliter of supernatant (Table 5).  In order to normalize the 
amount of virus used for each transduction, larger supernatant volumes of the low-titer  
 
Table 5.  Rat1a virus titers of wild type and mutant MLL/MLL2-AF9 retroviral 
fusion constructs. 
Retroviral Construct Virus Titer (CFUs) 
MSCV 1 x 106 
MLL-AF9 2 x 105 
w.t. MLL/MLL2-AF9 8.5 x 105 
A964R 1.4 x 106 
H968Q 8.0 x 105 
R970P 2.6 x 106 
V975P 5.2 x 104 
LRVQ973-6QVPE 1.3 x 106 
V982T 2.5 x 104 
P993R 7.5 x 105 
T995I 2.4 x 105 
V1001K 4.9 x 105 
VY1001-2KM 1.2 x 106 
R1011M 1.1 x 106 
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constructs were used during spinoculation so that an effective infection reaction could 
take place on the order of 105-106 CFUs per spinoculation reaction. 
MLL residues introduced into the MLL/MLL2-AF9 fusion protein showed variable 
ability to rescue transformation capacity in an in vitro colony assay 
 
An in vitro colony assay was performed to determine the functional importance of 
individual residues within the CXXC domain.  Bone marrow progenitor cells were 
isolated from C57Bl/6 mice via c-kit positive selection and were transduced with similar 
amounts of either wild type or mutant MLL/MLL2-AF9 retroviral constructs.  The 
MSCVneo empty vector retrovirus was used as a negative control, and infection with the 
well-characterized MLL-AF9 construct served as a positive control.  Cells were grown in 
the presence of G418 for the first round of plating to select for cells infected by retrovirus 
which express the MSCVneo vector neomycin resistance gene.  After the first round of 
growth, colony and cell numbers were counted and then the cells were serially replated 
for at least three rounds or until the cultures no longer produced colonies (Figure 12C).  
The numbers of colonies and cells were quantified in the third round as a measure of self-
renewal and cell proliferation capacity, respectively.  When non-transformed cells—like 
those infected with MSCVneo empty vector—were grown in methylcellulose in the 
presence of growth factors, the bone marrow progenitor cells were stimulated to undergo 
differentiation.  Eventually, the cells lost their proliferative capacity forming fewer and 
more diffuse colonies in early re-plating and failed to form any colonies by Round 3 
(Figures 14 and 15).  At the third round of plating, the non-transformed cells showed a 
differentiated morphology and generated diffuse colonies (Figure 15).  In contrast, cells 
transduced with the highly transforming MLL-AF9 formed large numbers of dense  
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Figure 14. In vitro self-renewal and proliferation capacity of MLL and 
MLL2 residues in the context of an AF9 fusion 
oncoprotein.  
(A) Colony forming units (CFUs) and
(B) Cell numbers from Round 3 of colony assay.
(Data represent the mean ± 1 S.D. from at least three independent experiments; p-
values determined by T-test for comparison to MLL/MLL2-AF9 levels)
(C) Correlation between CFUs and cell numbers from the control, wild type, and 
mutant fusion constructs used in the methylcellulose colony assay.
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colonies by Round 3 which continued to form colonies through a fifth round.  The tight 
colonies of MLL-AF9 transduced cells had distinct borders and are comprised of blast-
like cells with large nuclei and little cytoplasm (Figure 15). 
By the third round, the number of colonies formed by cells transduced by wild 
type MLL/MLL2-AF9 was decreased 7-fold relative to the MLL-AF9 transformed cells, 
and the total cell number was decreased 10-fold compared to the MLL-AF9 transduced 
cells (Figure 14).  These colonies more closely resembled those transduced with the 
empty vector negative control with a more diffuse colony morphology and comprised of 
cells with a differentiated morphology (Figure 15). 
The thirteen individual point mutant MLL/MLL2-AF9 constructs showed variable 
capacities to immortalize c-kit positive progenitor cells in vitro.  No single amino acid 
substitution was able to completely restore MLL/MLL2-AF9 transformation capacity 
back to the levels of MLL-AF9.  The measures of transformation capacity—colony 
formation and cell proliferation—showed a positive correlation when MLL residues were 
introduced into the MLL2 CXXC domain whereby those residues which showed higher 
colony forming ability also showed an increase in total cell number (Figure 14C).  The 
amino acid substitutions of A964R, R970P, LRVQ973-6QVPE, and VY1001-2KM 
showed the highest capacities to rescue transformation (with at least a 40% increase in 
self-renewal and cell proliferation) compared to the MLL/MLL2-AF9 construct.  The 
substitutions of P993R, T995I, and V1001K showed intermediate (20-40%) rescue of 
transformation ability while H968Q, V975P, V982T, and R1011M substitutions showed 
little or no (<20%) capacity to rescue cellular self-renewal or proliferation from baseline 
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levels of the wild type construct (Figure 14).  Colony and cellular morphologies of these 
mutant constructs also closely correlated with transformation capacities.  Those 
constructs causing the highest self-renewal capacity produced dense, tight colonies while 
those exhibiting little capacity for self-renewal generated small numbers of primarily 
diffuse colonies.  The dense colonies were comprised of blast-like cells resembling MLL-
AF9 transformed cells while the diffuse colonies consisted of mostly differentiated cells 
with large, vacuolated cytoplasm and relatively small nuclei.  The constructs with 
intermediate transformation capacities produced a mixture of dense and diffuse colonies 
consisting of both undifferentiated and differentiated cells (Figure 15).  These results 
indicate that there are individual amino acids of MLL that are able to functionally restore 
the phenotype of the MLL-AF9 fusion protein when introduced into the MLL2 CXXC 
domain.  These specific residues are critical for the transformation capacity of the CXXC 
domain and the leukemogenic capacity of MLL fusion proteins. 
MLL residues showed variable ability to rescue increased Hoxa9 expression when 
introduced into the MLL/MLL2-AF9 fusion protein in an in vitro colony assay 
 
 Hoxa9 is a well-studied target gene of MLL.  During normal hematopoiesis, 
regulated transcription allows Hoxa9 expression levels to decrease as a cell differentiates 
toward a more mature lineage and decreases the highly proliferative capacity of the 
immature precursor cells.  In leukemia cells harboring an MLL fusion protein, expression 
of the Hoxa9 gene is upregulated contributing to the maintenance of an undifferentiated 
state and to an unlimited capacity for proliferation and self-renewal of hematopoietic 
progenitor cells.  As an independent test for transformation capacity, transduced cells 
from the first round of the methylcellulose colony assay were collected to measure Hoxa9 
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expression.  RNA from these cells was isolated and reverse transcribed to generate 
cDNA.  Primers for the Hoxa9 locus were then used to amplify this specific mRNA 
transcript and levels were quantified via qRT-PCR. 
 As expected, the bone marrow progenitor cells expressing MLL-AF9 showed 
high levels of Hoxa9 expression (17-fold increase) compared to the empty vector 
MSCVneo (negative control).  The wild type MLL/MLL2-AF9 construct expressing the 
MLL2 CXXC and ‘post-CXXC’ residues showed a 10-fold reduction in Hoxa9 
expression levels compared to MLL-AF9.  The thirteen constructs encoding MLL amino 
acid substitutions within the MLL2 CXXC domain showed variable capacities to restore 
high Hoxa9 expression from the baseline levels of wild type MLL/MLL2-AF9 (Figure 
16A).  The expression levels of Hoxa9 positively correlated with colony formation and 
cell proliferation ability in which higher transforming constructs also exhibit higher 
levels of Hoxa9 expression (Figure 16B and 15C).  However, in contrast to the colony 
formation and cell proliferation numbers, some specific MLL amino acid substitutions 
(A964R and LRVQ973-6QVPE) were able to completely restore Hoxa9 expression to 
levels observed in MLL-AF9 transduced progenitor cells (p > 0.05 by Student’s T-test 
compared to MLL-AF9 Hoxa9 expression levels).  The MLL substitutions of R970P, 
V1001K, and VY1001-2KM showed intermediate (40-60%) rescue of target gene 
expression compared to the wild type level.  The constructs showing weak transformation 
capacity also showed low levels (<40%) of Hoxa9 expression compared to MLL-AF9: 
H968Q, V975P, V982T, P993R, T995I, and R1011M.  The ability of specific residues to 
restore Hoxa9 expression independently verifies the functional importance of the 
80 
 
 
Figure 16.  Hoxa9 expression from Round 1 colony assay cells.
(A) Quantification of Hoxa9 expression via qRT-PCR performed in triplicate 
using RNA isolated from colony assay cells from first plating (Round 1). Data was 
normalized to Hprt mRNA levels and set relative to empty vector MSCV 
(negative control) Hoxa9 levels (Mean ± 1 S.D; p-values were calculated by 
Student’s T-test for comparison to MLL/MLL2-AF9 expression levels).  Note that 
MSCV and R1011M values represent a statistically significant lower level of 
Hoxa9 expression compared to the MLL/MLL2-AF9 expression level in contrast 
to the other constructs which show increased Hoxa9 expression levels.  Also note 
that A964R and LRVQ973-6QVPE mutants showed complete restoration of 
Hoxa9 expression to MLL-AF9 levels (‡ indicates p > 0.05 by Student’s T-test 
when comparing expression to MLL-AF9 levels).
Correlation of Hoxa9 expression levels with
(B) colony forming units (CFUs) and
(C) cell numbers relative to MLL-AF9.
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residues that also rescued colony formation and cell proliferation ability.  Those residues 
which restored Hoxa9 expression levels to MLL-AF9 levels (or close to the same level) 
are important residues of the MLL CXXC domain contributing to the ability of MLL 
fusion proteins to transform hematopoietic progenitor cells. 
Aim 2: Determine the role of Cysteine 1188 in the regulation of the MLL CXXC 
domain binding to non-methylated CpG DNA 
 
Treatment of MLL-AF9 and MLL(C1188A)-AF9 cells with agents that can modify 
thiol groups 
 
Cysteine 1188 is the only non-zinc-coordinating cysteine residue within the 
CXXC domain of MLL.  This residue is positioned on the DNA-binding surface of the 
domain in the structure published by Cierpicki et al11.  I hypothesized that post-
translational modification of the thiol side chain of Cys1188 through oxidation or 
nitrosylation would inhibit the binding of the CXXC domain to its non-methylated target 
DNA.  Loss of DNA binding by the MLL CXXC domain would lead to decreased 
transformation capacity by the MLL fusion protein in an in vitro colony assay11.  In order 
to test this hypothesis, MLL-AF9-transformed cells were treated with increasing amounts 
of several agents that are known to oxidize (hydrogen peroxide and parthenolide) or 
nitrosylate (spermine nonoate) free thiol groups.  As a control, a transformed cell line 
expressing mutant MLL-AF9 fusion protein was used in which the cysteine at residue 
1188 was replaced with alanine11.  The methyl side chain of alanine is not reactive, so 
this specific amino acid position would remain unaffected by treatment with thiol-
reactive agents.  The CXXC domain containing this C1188A mutation was shown by our 
collaborators to bind to non-methylated CpG DNA with equal affinity to the wild type 
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domain11.  This MLL(C1188A)-AF9 fusion protein was also shown by our lab to 
transform bone marrow progenitor cells similar to MLL-AF911.  Should oxidation or 
nitrosylation modify the cysteine residue in a way that interferes with binding of the 
CXXC domain to DNA, the wild type MLL-AF9 cells should show a decreased 
transformation capacity compared to the mutant MLL(C1188A)-AF9 cells. 
A colorimetric, cellular proliferation assay using MTT reagent was performed to 
characterize potential the effects of oxidation or nitrosylation between the wild type 
MLL-AF9 and mutant MLL(C1188A)-AF9 transformed cell lines.  In the MTT assay, 
viable cells are able to internalize the tetrazolium salt reagent (yellow color) and reduce 
the compound in the mitochondria to a formazan salt product (purple color) in a manner 
that is dependent on the number of cells and the metabolic activity of the viable cells in 
the culture.  Those cells which are viable and rapidly proliferating will reduce more 
tetrazolium reagent to formazan to produce a darker purple color and result in an 
increased absorbance reading at 570 nm.  Wild type MLL-AF9 and mutant 
MLL(C1188A)-AF9 cells were serially diluted (0 to 200,000 cells per well) in a 96-well 
plate in triplicate to determine relative MTT activity of untreated cells and to determine 
the optimal number of cells for each treatment assay.  Independent of the number of cells, 
the wild type MLL-AF9 cells showed higher absorbance readings indicative of higher 
metabolic activity and greater cellular proliferation of the wild type cells compared to the 
mutant MLL(C1188A)-AF9 cells (Figure 17A).  30,000 cells was determined to be 
optimal for treatment as this number of cells had an absorbance reading near the middle 
of the linear portion of the cell titration curve.  This allowed for variation in absorbance  
83 
 
Figure 17. Effect of thiol modifying agents on proliferation of MLL-AF9 
versus MLL(C1188A)-AF9 transformed cells.
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• Spermine Nonoate
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A
(A) MTT assay absorbance readings for increasing wild type (W.T.) MLL-AF9 and 
MLL(C1188A)-AF9 cell number as a function of cell viability.
(B) Experimental design for treating cells and measuring cell viability.
Relative cell viability of W.T. MLL-AF9 or MLL(C1188A)-AF9 transduced cells 
following treatment with (C) hydrogen peroxide, (D) parthenolide, (E) or spermine 
nonoate.  Cell viability data is set relative to the untreated cell viability of MLL-AF9 
or MLL(C1188A)-AF9 transduced cells, respectively (Mean ± 1 S.D.).
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values depending whether cells would exhibit increased or decreased proliferation during 
the treatments.  The MTT results are presented as cell viability relative to untreated cells 
transduced with wild type MLL-AF9 or mutant MLL(C1188A)-AF9. 
Cells transduced with wild type (w.t.) MLL-AF9 or MLL(C1188A)-AF9 were 
treated with increasing amounts of hydrogen peroxide (0-14mM), parthenolide (0-10µM), 
or spermine nonoate (0-729µM).  (The ranges of doses used were based on those reported 
for other studies in the literature161-167.)  Cells were incubated with the compounds in 
culture medium for 18 hours followed by MTT assay measurement (Figure 17B). 
Treatment with all reagents showed a dose-dependent decrease in viable cell 
numbers in both transformed cell types (Figure 17C-E).  The effects of hydrogen 
peroxide and spermine nonoate on cell viability were similar for both the wild type and 
the mutant C1188A cells at all doses.  This was also true at higher doses of parthenolide 
treatment (5-10µM).  Lower doses of parthenolide (1-4µM) showed a greater decrease in 
cell viability of the mutant C1188A cells compared to the wild type cells.  This was 
contrary to my initial hypothesis and suggest that a more sensitive assay would be 
necessary to investigate the potential functional effects of oxidation or nitrosylation on 
Cys1188. 
 Next, I performed a methylcellulose colony assay as an independent method for 
measuring the longer-term effects on transformation capacity of these cells following 
treatment.  The same thiol-modifying agents from above were used to determine if any 
selective effect on self-renewal or proliferation could be observed.  Either wild type 
MLL-AF9 or mutant MLL(C1188A)-AF9 transduced cells were treated as before for 18 
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hours in liquid culture with increasing doses of hydrogen peroxide (0-200µM), 
parthenolide (0-5µM), or spermine nonoate (0-32µM).  After incubation, cells and culture 
media containing the compounds were plated in semi-solid methylcellulose.  Cells were 
incubated for five days and colony and cell numbers were then quantified and compared 
(Figure 18A).  As with the MTT assay, hydrogen peroxide, parthenolide, and spermine 
nonoate treatments showed dose-dependent effects on both the wild type and mutant-
transduced cells with increasing doses showing fewer numbers of colonies and cells 
(Figure 18B-D).  Parthenolide treatment also showed dose-dependent toxicities for both 
cell types.  In this longer-term assay, a modest decrease in colony and cell numbers was 
observed in the wild type MLL-AF9 transduced cells compared to the mutant 
MLL(C1188A)-AF9 transduced cells at intermediate doses of parthenolide (1.5 and 
2.5µM) (Figure 18C, note asterisks).  At these intermediate doses of parthenolide, the 
self-renewal and cell proliferation capacities of wild type MLL-AF9 transduced cells 
were more susceptible to parthenolide treatment than the mutant MLL(C1188A)-AF9 
cells.  This result suggests that the cysteine 1188 residue may have a functional role in 
contributing to the colony forming ability of MLL fusion proteins since the only 
difference between these two cell types is a cysteine versus alanine at this position within 
the CXXC domain.  It is possible that Cys1188 is modified by intermediate doses of 
parthenolide in a way that alters CXXC DNA-binding affinity ultimately prevents 
cellular immortalization. 
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Figure 18. Effect of thiol modifying agents on self-renewal and 
proliferation of MLL-AF9 versus MLL(C1188A)-AF9 
transformed cells.
A
B
C
(A) Experimental schematic for treating wild type (W.T.) MLL-AF9 or 
MLL(C1188A)-AF9 cells with thiol-modifying agents.
Dose-dependent effects of (B) hydrogen peroxide, (C) parthenolide, or (D) spermine 
nonoate treatment on colony forming ability—measured as colony forming units, 
CFUs—(left) and cellular proliferation (right). Results represent the averages of three 
independent experiments and are set relative to the CFUs or cell numbers for 
untreated MLL-AF9 or MLL(C1188A)-AF9 transduced cells, respectively.
(Mean ± 1 S.D., p-values determined by Student’s T-Test)
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Growth of MLL-AF9 and MLL(C1188A)-AF9 transduced cells under conditions of 
varying oxygen concentration 
 
 The modest effects on the colony forming ability of MLL-AF9 transduced cells 
compared to those transduced with MLL(C1188A)-AF9 following parthenolide treatment 
suggested that the cysteine 1188 residue of MLL’s CXXC domain may be susceptible to 
oxidation by parthenolide’s induction ROS which could oxidize the thiol side chain of 
Cys1188 to abrogate DNA-binding and decrease colony forming potential.  To further 
test whether potential oxidation of cysteine 1188 could alter transformation capacity, the 
MLL-AF9 and MLL(C1188A)-AF9 transformed cells were grown under conditions of 
varying oxygen concentration.  I hypothesized that lower oxygen concentrations (1-5% 
O2) would mimic the hypoxic bone marrow niche in which hematopoietic stem and 
progenitor cells reside.  In this environment, cells undergo less aerobic respiration 
resulting in fewer metabolic ROS which could potentially oxidize the free thiol group of 
Cys1188.  In contrast, the higher experimental concentrations of oxygen (21-60% O2) 
would expose the wild type MLL-AF9 and mutant MLL(C1188A)-AF9 cells to higher 
levels of ROS, in turn, inducing the potential oxidation of Cysteine 1188 (reversible or 
irreversible) and alter the transformation capacity of the oncogenic MLL fusion protein 
through altered DNA-binding affinity.  I hypothesized that a hypoxic environment like 
the bone marrow niche would maintain the free thiol side group of Cys1188 in a reduced 
state allowing the MLL CXXC domain to bind to DNA while an environment with 
increased oxygen would increase the potential for thiol oxidation of Cys1188 leading to 
disruption of DNA-binding and ultimately decreasing the transforming ability of the 
MLL-AF9 fusion protein. 
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 At all concentrations of oxygen (1-60% O2), the control MLL(C1188A)-AF9 cells 
showed a lower number of colonies compared to the wild type MLL-AF9 cells (Figure 
19A).  This finding corresponded with the initial cell titration of this Aim 2 in which the 
wild type MLL-AF9 transduced cells showed greater MTT activity (i.e. indicating a 
greater overall cell viability and/or greater metabolic activity) than the mutant 
MLL(C1188A)-AF9 transduced cells (Figure 17A).  In order to account for this inherent 
difference, the colony forming units (CFUs) were normalized to growth under room air 
(21% O2) conditions (Figure 19B).  This normalized data revealed only slight fluctuations 
in colony forming ability from 1 to 21% O2 with no statistically significant difference 
between the wild type and mutant cells.  Both transformed cell types showed a marked 
decrease in numbers and sizes of colonies under conditions of 60% O2 demonstrating that 
both cell types are sensitive to hyperoxia, though, the effects were not more pronounced 
for the wild type MLL-AF9 cells compared to the control MLL(C1188A)-AF9 cells as I 
had predicted.  Given that the treatment of MLL-AF9 transduced cells with thiol 
modifying agents and growth under varying oxygen concentrations generated only 
modest results, more sensitive experiments will need to be conducted in the future to 
ultimately determine whether Cys1188 of MLL may be subject to redox regulation which 
would allow this residue to function as a molecular switch that modulates DNA-binding 
affinity of the CXXC domain. 
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Figure 19. Effects of varying oxygen concentration on colony 
forming ability of MLL-AF9 versus MLL(C1188A)-AF9 
transformed cells.
(A) Effects of varying oxygen concentration on colony forming ability—
measured as colony forming units, CFUs—of wild type MLL-AF9 or 
MLL(C1188A)-AF9 cells.
(B) Colony forming ability (measured as CFUs) set relative to CFUs under 21% 
oxygen concentration for each respective cell type: W.T. MLL-AF9 and 
MLL(C1188A)-AF9.
Data represent averages from two to eight independent experiments (Mean ± 1 
S.D.); p-values were determined by Student’s T-test comparing CFUs of W.T. 
MLL-AF9 to MLL(C1188A)-AF9 at each oxygen level (*,**,***) or comparing 
CFUs of 21% oxygen to CFUs at other oxygen levels (+,++,+++).
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CHAPTER 5 
 
DISCUSSION 
 
 Through a complex set of interactions involving DNA, histones, and other 
transcription factors, MLL fusion proteins participate in the epigenetic misregulation of 
HOX genes in leukemias with rearrangements of the MLL gene.  The N-terminal portion 
of MLL—including the CXXC domain and ‘post-CXXC’ residues—is essential for the 
immortalizing capabilities of MLL fusions.  It is not completely understood, though, 
which specific residues within the CXXC domain of MLL are necessary for 
leukemogenesis, nor how they mediate this function.  The goal of my dissertation project 
was to identify critical amino acids of the MLL CXXC domain in the context of MLL 
fusion protein-mediated cell immortalization.  From my studies, we could gain a better 
understanding of the mechanism by which MLL causes leukemia and ultimately identify 
residues which could be targeted by future therapies for MLL associated leukemias. 
 I used MLL2, the closest homolog of MLL, as a model to identify functionally 
critical residues of the CXXC domain within the context of the well-characterized MLL-
AF9 fusion protein.  Interestingly, MLL2 has not been found in chromosomal 
translocations associated with leukemia, and the N-terminus of MLL2 cannot 
functionally substitute for MLL in cell immortalization assays7.  To study differences 
between the specific residues of the MLL and MLL2 CXXC domains, I first generated a 
fusion protein in which the MLL2 CXXC domain was swapped into MLL-AF9 to 
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generate a synthetic MLL/MLL2(CXXC)-AF9 fusion protein.  This chimeric fusion 
protein—in which only the CXXC domains of MLL and MLL2 were exchanged—was 
still capable of transforming primary hematopoietic cells.  This finding suggested that 
there is enough homology between these two domains that the MLL and MLL2 CXXC 
domain can functionally substitute for one another and that there are likely other critical 
residues outside of MLL’s CXXC domain that are able to compensate for amino acid 
differences introduced by the MLL2 CXXC domain.  The MLL and MLL2 CXXC 
domains share about 60% homology including the highly conserved zinc-coordinating 
cysteine residues found in the MLL CXXC domain that are essential for the proper 
folding and stability of the domain143.  Even with this degree of homology, though, 
differences in DNA-binding affinity have been observed by our collaborators at the 
University of Virginia.  The isolated MLL2 CXXC domain shows nearly a four-fold 
decrease in binding affinity for the same non-methylated CpG dinucleotides as the 
isolated MLL CXXC domain (Table 6, Bushweller Lab, unpublished data) suggesting 
that the amino acid differences between the MLL and MLL2 CXXC domains have 
functional significance. 
 In order to more effectively study the role of these potentially critical residues 
within MLL’s CXXC domain, additional amino acids comprising the ‘post-CXXC’ 
region of MLL2 were introduced into the chimeric MLL/MLL2-AF9 fusion protein along 
with MLL2’s CXXC domain.  The amino acid sequence of the MLL2 ‘post-CXXC’ 
region aligns with the ‘post-CXXC’ residues of MLL which constitute the repression 
domain which our lab has previously shown binds to co-repressor proteins HDAC1, 
CtBP, HPC2, and BMI-1.  More recently, it was determined that the MLL CXXC and 
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post-CXXC domain could also interact with the PAF coactivator complex9, 10.  With only 
about 30% homology between MLL and MLL2 in this larger region, it was possible to 
reduce transformation ability by removing even more MLL residues and was perhaps also 
likely to alter the functional binding of co-repressor or co-activator proteins that could 
ultimately contribute to the differential leukemogenic potential of the fusion protein.  The 
transformation capacity of this MLL/MLL2-AF9 fusion protein was now significantly 
reduced by nearly seven-fold compared to that of MLL-AF9.  Using this wild type 
chimeric protein, which showed only limited transformation capacity in vitro, I now had 
a baseline from which I could attempt to restore colony forming ability and cellular 
proliferation through the introduction of individual residues of MLL. 
 Thirteen amino acid substitutions were introduced into the CXXC domain of the 
synthetic MLL/MLL2-AF9 fusion which restored the residues to the MLL sequence.  In 
vitro colony assay results showed variable capacities of these residues to rescue colony 
formation and cellular proliferation compared to MLL-AF9.  There was a positive 
correlation between the ability of a point mutation to restore cellular transformation and 
to rescue the level of Hoxa9 expression: Those constructs that generated more colonies 
and cell numbers by the third round of plating in vitro also exhibited higher levels of 
Hoxa9 expression after only one round of plating in vitro.  The relationship between the 
functional transformation data and the structure of the CXXC domain is shown in Figure 
20.  The residues in Figure 20 are colored according to their ability to restore (in part or 
in whole) leukemogenic capacity of the chimeric fusion protein.  Residue substitutions 
that were able to restore function are located on both the DNA-contact surface of the 
CXXC domain and on the opposite, non-DNA contacting surface.  The residue  
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GKKMRMARCGHCRGCLRVQDCGSCVNCLDKPKFGGPNTKKQCCVYRKCDKIEARKME
KKGRRSRRCGQCPGCQVPEDCGVCTNCLDKPKFGGRNIKKQCCKMRKCQNLQWMPSK
A
B
90° 90°
90°
90°
Figure 20. Structure-function relationship between residues of the 
CXXC domain
High Low
Hoxa9 expression level
MLL2: P993
MLL: R1182
MLL2: A964
MLL: R1153
MLL2: V975
MLL: P1164
MLL2: LRVQ973-6
MLL: QVPE1162-5
MLL2: H968
MLL: Q1157
MLL2: VY1001-2
MLL: KM1190-1
MLL2: V982
MLL: T1171
MLL2: R970
MLL: P1159
MLL2: V1001
MLL: K1190
MLL2: R1011
MLL: M1200
MLL2: T995
MLL: I1184
(A) Sequence alignment of the MLL and MLL2 CXXC domain highlighting the 
substituted residues by their ability to rescue Hoxa9 expression levels within the 
context of the MLL/MLL2-AF9 fusion protein.
(B) The MLL CXXC domain in four orientations showing amino acids as a space-
filled model and colored according to the ability of the residue(s) to rescue Hoxa9
expression levels within the MLL/MLL2-AF9 fusion protein.  (DNA is shown as a 
ball-and-stick model.)
aa1147
aa958
aa1203
aa1014
MLL
MLL2
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substitutions on the DNA-contact surface (i.e. A964R, P993R, T995I, V1001K, VY1001-
2KM) could play a direct role in altering DNA-binding affinity.  In contrast, those 
residues showing altered function that are on the opposite surface (i.e. R970P and 
LRVQ973-6QVPE) could play an indirect role on DNA-binding affinity through 
allosteric effects  by altering the conformation of the domain or could potentially alter 
interactions with other proteins through changes in conformation or surface charges. 
In vitro binding studies were conducted to see if any of these amino acid 
substitutions within the CXXC domain could alter DNA binding or binding to other 
cofactor proteins previously shown to interact with the MLL repression domain.  
Aravinda Kuntimaddi (from the Bushweller laboratory at the University of Virginia) 
performed preliminary studies on isolated CXXC domain to test DNA-binding affinity 
(Table 6).  The A964R substitution within the MLL2 CXXC domain was able to almost 
completely restore DNA binding affinity to the level of MLL.  This finding along with 
the functional colony assay data with this substitution confirms the importance of CXXC 
domain binding to DNA that was previously shown by our labs11.  In the NMR solution 
structure of the MLL CXXC domain complexed with DNA, this residue (arginine 1153 in 
MLL) was not shown to form a direct interaction with the DNA.  The flanking residues, 
however, both contact the phosphate backbone so R1153 of MLL may help to stabilize 
these interactions to increase DNA-binding affinity11. 
Table 6.  DNA binding affinities of isolated wild type and mutant CXXC domains. 
CXXC Domain Kd (µM) 
wt MLL 90 
wt MLL2 340 
A964R MLL2 96 
R1011M MLL2 170 
Data provided by Aravinda Kuntimaddi & John Bushweller, PhD (University of Virginia) 
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 The DNA binding affinity of the R1011M MLL2 CXXC mutant was also 
determined by the Bushweller lab.  This substitution showed a fifty percent restoration of 
DNA binding affinity, yet in contrast to the A964R substitution, this partial increase in 
affinity did not manifest in a rescue of transformation capacity.  In fact, the R1011M 
substitution showed no increase in colony forming ability and a decrease in Hoxa9 
expression compared to the wild type fusion protein.  This finding suggests that there 
may be a minimum DNA-binding affinity of the CXXC domain necessary for conferring 
the capacity for transformation to the fusion proteins.  Additional DNA-binding studies 
will need to be performed to determine if altered DNA binding accounts for the 
functional rescue observed for any of the other residue substitutions (i.e. R970P, 
LRVQ973-6QVPE, or V1001K).  I hypothesizethat the V1001K substitution, in 
particular, could increase DNA-binding affinity, as the lysine residue in this position 
(K1190 of MLL) was previously shown to form an electrostatic interaction with the 
phosphate backbone of DNA11.  Reintroducing the positively charged side group of 
lysine in this position would likely enhance the ability of the MLL2 CXXC domain to 
bind to DNA and account for the partial functional restoration of both the V1001K and 
the VY1001-2KM substitutions. 
 I performed in vitro binding studies between co-repressors or PAF1 and the 
isolated wild type or mutant repression domains using a subset of the constructs from the 
functional colony assay studies.  The three constructs showing the greatest rescue of 
function (colony formation, cell proliferation, and Hoxa9 expression) were chosen—
A964R, R970P, and LRVQ973-6QVPE—along with a substitution showing intermediate 
restorative effects (V1001K).  The R1011M substitution was also studied for comparison 
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to the wild type MLL1/2 repression domain since this mutant construct showed equally 
low transformation capacity as the wild type MLL/MLL2-AF9 fusion protein in the 
methylcellulose colony assay. 
 The MLL repression domain showed similar binding to co-repressors HDAC1 
and CtBP compared to the chimeric MLL1/2 repression domain containing ‘pre-CXXC’ 
residues from MLL and residues from MLL2 comprising the CXXC domain and ‘post-
CXXC’ region.  This construct was the equivalent “repression domain” present in the 
fusion constructs used in the colony assay and was cloned for this in vitro binding study 
so that I could determine whether altered co-repressor binding could account for 
differences in any of the functional data observed with the studied chimeric fusions.   
Each of the five amino acid substitutions that were tested showed relatively similar 
amount of binding to HDAC1 and CtBP compared to wild type MLL or MLL1/2 
repression domain constructs.  The minimal reduction in HDAC1 binding that was 
observed for the R970P construct compared to the MLL1/2 construct (p > 0.05) cannot 
alone account for the observed functional changes in the colony assay, however, because 
the R1011M construct (which showed no functional rescue) also exhibited a slight 
decrease in HDAC1 binding, though, the differences in binding were not statistically 
significant (p > 0.05).  Likewise, the increased CtBP binding by V1001K was 
comparable to the increase observed with the R1011M mutant protein. 
 The in vitro binding studies using the repression domain constructs showed 
enhanced binding of HPC2 to the MLL1/2 repression domain compared to the MLL 
repression domain.  The wild type MLL1/2 construct showed at least a two-fold increase 
in binding to HPC2 compared to the MLL repression domain; however, when the results 
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of multiple experiments were averaged together, this binding difference did not achieve 
statistical significance due to the dynamic range of the band intensities between 
experiments.  The amino acid substitutions observed in the binding studies (A964R, 
R970P, LRVQ973-6QVPE, V1001K, and R1011M) showed no difference (p > 0.05) in 
binding when compared to the MLL1/2 repression domain.  This finding suggests that 
HPC2 binding does not account for the functional differences observed for the fusion 
proteins that were studied in the in vitro transformation assay.  Future interaction studies 
between MLL and other cofactor proteins will need to be performed to account for any 
functional differences between the mutant constructs which are not explained solely by 
differences in DNA-binding affinity.  Our laboratory has previously shown that the 
polycomb group protein BMI-1 also interacts with the MLL repression domain8.  
Differential binding of BMI-1 to the mutant repression domain constructs has yet to be 
explored and could potentially explain the functional differences observed for some of 
the mutant MLL/MLL2-AF9 constructs.  Screening for other proteins which interact with 
the MLL repression domain may also yield additional candidates for future in vitro 
binding studies. 
Recent studies have implicated a role for the polymerase associated factor 
complex (PAFc) in MLL leukemia9, 10.  MLL directly interacts with PAFc through an 
interaction with the PAF1 subunit in the regions flanking the CXXC domain.  Sequential 
deletion studies determined the minimal interaction domain to include residues of the 
MLL ‘pre-CXXC’ (residues 1115-1154) and the MLL ‘post-CXXC’ (residues 1209-
1299) region which together are found within the repression domain of MLL 
(functionally defined as MLL residues 1100-1400)3, 10.  PAFc interacts with the MLL-
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AF9 fusion protein to help in the recruitment of the fusion and to enhance Hoxa9 
expression.  Mutation and deletion studies showed that loss of the PAFc interaction 
prevented recruitment of MLL or MLL fusions to target gene promoters and for 
transformation in vitro9, 10. 
My in vitro binding studies confirmed that the MLL repression domain directly 
interacts with the PAF1 protein subunit of PAFc.  Using the chimeric MLL1/2 repression 
domain construct made up of the analogous repression domain from the minimally 
transforming fusion protein, I found that PAF1 is able to bind directly in equal amounts 
compared to the MLL repression domain.  It was previously shown that a region of 
MLL2 comprised of the residues flanking the CXXC domain was unable to bind to PAF1 
(presumably residues 900 to roughly 1042 of MLL2; the actual residues are not reported 
in the publication)9.  The difference in findings might be attributed to the ‘pre-CXXC’ 
residues which, in my construct, are from MLL and were shown by Muntean et al. to be 
essential for binding PAF1 or perhaps also attributed to the extended ‘post-CXXC’ 
residues from MLL2 in my constructs which would align with the full repression domain 
from MLL10.  The structure and function of the MLL and MLL2 ‘post-CXXC’ regions 
have yet to be determined.  Future studies will be necessary to understand the specific 
role of this region in normal MLL function and in the functioning of leukemogenic fusion 
proteins. 
Of particular interest is a R1153A mutation (R1153 of MLL mutated to alanine) 
studied by Milne et al. in an interaction between PAF1 and a mutant MLL construct 
comprised of the first half of the MLL repression domain (MLL residues 1101-1250)9.  
This is the exact opposite mutation which I had generated within the MLL2 CXXC 
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domain—A964R—in which an alanine is present in this position in MLL2 and an 
arginine in MLL.  The authors show that introducing this single R1153A mutation into 
MLL disrupts the interaction of PAF1 even when critical residues flanking the MLL 
CXXC domain are still present as were shown to be necessary for interaction with PAF1 
by Muntean et al9, 10.  At the same time, the authors speculate that this mutation does not 
alter DNA-binding affinity based on the findings of an electrophoretic mobility shift 
assay (EMSA) using the MLL2 CXXC domain which has an alanine in this position7.  In 
contrast to this hypothesis, though, our collaborators have now shown through a 
quantitative method (NMR titration) that an alanine residue in this position of the CXXC 
domain does indeed alter DNA binding affinity (Table 6) and the reverse mutation in the 
MLL2 CXXC domain (A964R) nearly completely restores DNA affinity levels to that of 
the MLL CXXC domain. 
When individual amino acid substitutions from MLL were introduced into the 
MLL1/2 repression domain, I observed no altered PAF1 binding for any of the isolated 
GST-tagged constructs (p > 0.05).  The absence of a change in binding is likely due to the 
equal binding of PAF1 to both the wild type MLL and the wild type MLL1/2 repression 
domains so that introduction of MLL residues into the MLL1/2 construct would not 
enhance or disrupt binding to any great extent.  This finding of unaltered PAF1 binding 
between the wild type MLL and MLL1/2 repression domains and the mutant repression 
domains is significant given the previous findings that PAF1 recruitment is necessary for 
leukemogenesis.  This finding demonstrates that the PAF1 interaction with MLL—while 
it may be necessary—is not sufficient to confer a transforming capacity to an MLL fusion 
protein. 
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Furthermore, the findings of PAF1 binding to all repression domain constructs 
along with the in vitro DNA-binding data of our collaborators help to distinguish the 
importance of PAF complex recruitment from the ability of MLL to bind to its non-
methylated DNA targets.  The wild type MLL and MLL1/2 repression domain constructs 
are both able to bind to PAF1, suggesting that the PAF complex would be subsequently 
recruited to target loci.  However, my functional colony assay data showed differences in 
transformation abilities of the MLL-AF9 and MLL/MLL2-AF9 fusion proteins as the 
latter formed only minimal colonies comprised of differentiated cells.  Significantly, the 
MLL/MLL2-AF9 transduced bone marrow cells showed only minimal increase in Hoxa9 
expression levels compared to the negative control even though PAF1 is able to bind to 
the chimeric repression domain and would be expected to enhance gene transcription 
through recruitment of PAFc, as reported previously.  There were significant differences 
observed in DNA-binding affinities, however, between the wild type MLL and MLL2 
CXXC domains and the A964R CXXC domain.  The A964R mutation nearly restored 
DNA binding affinity while showing no alteration of PAF1 binding to the repression 
domain construct in vitro (i.e. no increased binding to PAF1 as might have been expected 
with this reverse mutation according to the previous report by Milne et al9) demonstrating 
that DNA binding of the CXXC domain mediated by the MLL R1153 residue is of 
paramount importance for leukemogenesis and recruitment of PAFc may be a subsequent 
step in the process of transformation.  A chromatin immunoprecipitation experiment 
looking at co-recruitment of PAF and the fusion protein to the Hoxa9 promoter would 
further substantiate this conclusion. 
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Table 7.  Summary of functional in vitro transformation and DNA-binding data. 
 
Cell 
Transformation 
Hoxa9 
Expression 
DNA 
binding 
MLL ++++ ++++ +++ 
MLL1/2 + + + 
A964R ++ ++++ +++ 
H968Q + ++ ND 
R970P +++ +++ ND 
V975P + ++ ND 
LRVQ973-6QVPE ++ ++++ ND 
V982T + + ND 
P993R ++ ++ ND 
T995I ++ ++ ND 
V1001K ++ +++ ND 
VY1001-2KM ++ +++ ND 
R1011M + - ++ 
Symbols indicate approximate 2-3 fold (++), 4-5 fold 
(+++), or >5 fold (++++) increase in functional activity 
compared to baseline MLL1/2 levels (+), a relative 
reduction (-) in activity compared to MLL1/2, or data not 
determined (ND) 
 
A summary of the results from my studies comparing residues of the MLL and 
MLL2 CXXC domains are shown Table 7.  Taken together, the results suggest a model 
whereby specific residues on both the inner DNA-contact surface and on the opposite, 
non-DNA-contact surface of the MLL CXXC domain (i.e. R1153 and QVPE1162-5 of 
MLL) are critical for the transformation capacity of an MLL fusion protein (Figure 21).  
The arginine 1153 residue of MLL has now been determined by our collaborators to 
increase DNA-binding affinity when introduced into the MLL2 CXXC domain (A964R 
substitution).  In contrast to the MLL, the CXXC domain of MLL2 shows a lower affinity 
for non-methylated DNA.  This difference can be attributed to the absence of a positive 
charge at this position in MLL2 (A964 of MLL2 versus R1153 of MLL) which could 
form an electrostatic interaction with the negatively charged phosphate backbone of the 
DNA to enhance binding.  The role of the critical residues on the outer CXXC domain 
surface (i.e. P1159 and QVPE1162-5 of MLL) has yet to be determined as these residues  
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Figure 21. Models of the MLL and MLL2 CXXC domains showing 
differential DNA binding and equivalent binding to 
cofactor proteins.
A
B
(A) Model of the MLL CXXC domain (green space-filling model) showing binding 
with high affinity to DNA (ball-and-stick model) dependent on R1153 of MLL (A964 
in MLL2).
(B) Model of MLL2 CXXC domain (blue space-filling model) showing weaker 
binding to DNA (ball-and-stick model) through A964 of MLL2 (R1153 in MLL).
(Note that both CXXC domains show similar binding to cofactor proteins HDAC1, 
HPC2, CtBP, and PAF1.  A patch of 4 residues (MLL QVPE1162-1165 and MLL2 
LRVQ973-6) which showed high functional restoration of colony forming ability and 
Hoxa9 expression are highlighted in red on the opposite, non-DNA contact surface.)
MLL2 CXXC
MLL CXXC
HDAC1
HPC2
PAF1
CtBP
HDAC1
HPC2
PAF1
CtBP
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did not significantly alter binding of cofactor proteins (HDAC1, HPC2, CtBP, and PAF1) 
in a way that corresponded to the observed transformation capacities.  It is possible that 
DNA-binding studies of the isolated domains may reveal that residue differences on the 
outer surface may have an impact on DNA binding affinity perhaps through allosteric 
changes within the CXXC domain.  In both models of Figure 21, it is the ability of the 
CXXC domain to bind to DNA that allows for the recruited PAF complex to enhance 
transcription of target genes and ultimately contribute to leukemogenesis. 
The second aim of my dissertation focused on the role of MLL’s Cys1188, the 
only non-zinc coordinating cysteine residue within the CXXC domain.  This residue is 
conserved in the CXXC domains of vertebrate MLL orthologs and also in the MLL2 
CXXC domain.  The proliferation and colony forming ability of MLL-AF9 transduced 
cells was measured following treatment with various thiol modifying agents.  MTT 
assays and colony formation assays showed dose-dependent toxicities of MLL-AF9 (and 
control MLL(C1188A)-AF9) cells treated with hydrogen peroxide, parthenolide, and 
spermine nonoate. 
Hydrogen peroxide is a strong oxidizing agent capable of undergoing the Fenton 
reaction in which reactive oxygen species are generated.  These free radicals can, in turn, 
oxidize free thiol groups in a reversible (i.e. induction of disulfide bond formation) or an 
irreversible (i.e. sulfonic acid formation) manner.  Several reports have shown that 
growth factor stimulation of hematopoietic cells induces the production of intermediate 
levels of reactive oxygen species (ROS) that activate signaling pathways to mediate cell 
cycle progression implicating a role for ROS in normal hematopoiesis and leukemia 
development161, 162, 168.  However, at higher levels like those observed with treatment of 
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high concentrations of hydrogen peroxide, ROS is damaging to DNA, proteins, and lipids 
causing an induction of apoptosis.  Increases in programmed cell death at high levels of 
hydrogen peroxide treatment likely accounted for the decreased proliferation and colony 
forming ability of both the MLL-AF9 and control MLL(C1188A)-AF9 cells in the MTT 
and colony formation assays. 
Parthenolide is a sesquiterpene lactone derived from the feverfew plant 
(Tanacetum parthenium) which has been used for aboriginal medicinal purposes ranging 
from treatment of headaches to inflammatory disorders169.  The lactone ring and epoxide 
group of parthenolide are susceptible to nucleophilic attack by reactive side chains 
including sulfydryl groups.  Parthenolide has recently gained interest as an anti-cancer 
compound for its ability to induce formation of intracellular reactive oxygen species and 
mediate apoptosis through oxidative stress163, 170, 171.  This increase in ROS could then 
cause oxidation of free thiol groups like Cys1188 of the MLL CXXC domain and 
potentially interfere with DNA binding.  Interestingly, parthenolide has also been shown 
to decrease DNA methylation by DNA methyltransferase 1 (DNMT1) through alkylation 
of a free thiol side group within the catalytic site172.  It is possible that parthenolide could 
form a similar covalent adduct to MLL’s Cys1188 through a Michael’s reaction which 
would sterically interfere with the binding of the CXXC domain to its non-methylated 
DNA targets. 
The MTT assays and colony forming assays showed dose-depdendent toxicities of 
parthenolide on MLL-AF9 and the control MLL(C1188A)-AF9 cells.  Unlike hydrogen 
peroxide and spermine nonoate, however, the MLL-AF9 cells showed a modest 
sensitivity to parthenolide treatment compared to the mutant control cells at intermediate 
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treatment concentrations.  Since the only difference in these cell lines is the Cys1188 
residue, it can be concluded that this non-zinc-coordinating cysteine residue has a minor 
effect on cell proliferation and colony formation in the context of the in vitro colony 
assay.  The modest affect of parthenolide on Cys1188 of the MLL CXXC domain may be 
associated with the indirect increase of intracellular ROS or with a direct binding of the 
lactone ring to the thiol side group.  The exact mechanism for this effect was not 
determined in my colony assay studies.  It would be possible to determine if a covalent 
parthenolide adduct is present through tandem mass spectrometry in which the MLL-AF9 
fusion protein could be purified from a large number of treated cells using the fusion 
protein’s FLAG tag.  If a spectral shift corresponding to parthenolide’s molecular weight 
is observed compared to untreated MLL-AF9 protein, it can be concluded that 
parthenolide covalently modifies Cys1188 to perturb the transformation capacity of 
MLL-AF9 cells.  In contrast, the lack of a spectral shift from treated MLL-AF9 protein 
might indicate that the generation of ROS could reversibly oxidize Cys1188 to alter 
fusion protein function.  An in vitro DNA-binding study could also be performed to 
determine the direct DNA-binding effects of parthenolide treatment on the isolated MLL 
CXXC domain.  Ultimately, the toxicity of parthenolide on MLL-AF9 cells is likely 
mediated through programmed cell death pathways as previously reported for many 
AML cell types165. 
Treatment of MLL-AF9 and control cells with spermine nonoate showed dose-
dependent cellular toxicities for both cell lines and, like hydrogen peroxide treatment, no 
significant differences in effects were observed between proliferation and colony 
formation of the either cell type.  Spermine nonoate is a nitric oxide (NO) donor that has 
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previously been shown to have anti-proliferative effects on tumor cells through inhibition 
of cell cycle progression and induction of cellular necrosis166, 167.  Treatment of MLL-
AF9 wild type and mutant cell lines did not show differential sensitivities to spermine 
nonoate treatment which was equally toxic at high concentrations.  While moderate 
amounts of NO are known to stimulate the mobilization of hematopoietic cells, higher 
levels of NO appear to be cytotoxic to leukemia cells in the in vitro MTT and colony 
assays45. 
 The treatment of MLL-AF9 cells with thiol modifying agents and growth of these 
cells under varying oxygen levels yielded only modest results.  It still remains to be more 
clearly determined whether Cys1188 is susceptible to redox regulation that would allow 
this residue to function as a molecular switch to modulate binding of the CXXC domain 
to DNA.  Treatment of cells with a wider array of oxidizing agents may confirm the 
modest effects observed by parthenolide, though, a more sensitive assay would be useful 
for determining altered effects on Cys1188 as global treatment effects (i.e. oxidation of 
free thiol groups throughout the cell and induction of oxidative stress) may have masked 
the specific effects of an individual cysteine residue.  An in vitro DNA-binding study in 
which the isolated CXXC domain is treated with possible modifying agents could 
measure the direct DNA-binding effects of any potential Cys1188 changes.  In addition, 
tandem mass spectrometry could be used to screen for possible modifications of Cys1188 
from purified MLL-AF9 fusion proteins.  Any spectral shifts associated with the Cys1188 
residue could be evaluated to determine what modification(s) may be present at this 
particular position.  If and when it is definitively determined how potential Cys1188 
modifications can alter the function of the CXXC domain, the susceptible side chain of 
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Cys1188 could be targeted with therapies to alter functions of the leukemogenic MLL 
fusion protein.  
 Ultimately, the CXXC domain of MLL may be an ideal target for future therapies 
for MLL-associated leukemias.  The requirement of this domain for transformation of 
hematopoietic cells suggests that disruption of critical interactions within this domain 
would offer some hope for patients.  By comparing the residues of the MLL and MLL2 
CXXC domains, critical amino acids were identified on both the DNA contact surface 
and the opposite, non-DNA contact surface that contribute to leukemogenic capacity.  
Small molecule inhibitors against the DNA-binding surface of the MLL CXXC domain 
would be particularly effective if the target includes the critical R1153 residue leading to 
disruption of DNA binding.  In addition, leukemia treatments that target the hypoxic bone 
marrow niche may also selectively target the leukemic stem cell populations that give rise 
to the burden of leukemia cells and subsequent relapse of disease.  Currently, the 
therapies for MLL-associated leukemia are limited, resulting in poor clinical outcomes.  
Knowledge of specific residues within the MLL CXXC domain which are critical to the 
leukemogenic capacity of MLL fusions may offer improved strategies for treating these 
aggressive forms of leukemia. 
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